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ABSTRACT
Lee B. Mullin: Ultrasound Mediated Nanoparticle Drug Delivery.
(Under the direction of Paul A. Dayton)
Ultrasound is not only a powerful diagnostic tool, but also a promising therapeutic
technology that can be used to improve localized drug delivery. Microbubble contrast
agents are micron sized encapsulated gas filled bubbles that are administered intra-
venously. Originally developed to enhance ultrasound images, microbubbles are highly
echogenic due to the gas core that provides a detectable impedance difference from the
surrounding medium. The core also allows for controlled response of the microbubbles
to ultrasound pulses. Microbubbles can be pushed using acoustic radiation force and
ruptured using high pressures. Destruction of microbubbles can increase permeability
at the cellular and vascular level, which can be advantageous for drug delivery.
Advances in drug delivery methods have been seen with the introduction of nanopar-
ticles, nanometer sized objects often carrying a drug payload. In chemotherapy, nanopar-
ticles can deliver drugs to tumors while limiting systemic exposure due to abnormalities
in tumor vasculature such large gaps between endothelial cells that allow nanoparticles
to enter into the interstitial space; this is referred to as the enhanced permeability and
retention (EPR) effect. However, this effect may be overestimated in many tumors.
Additionally, only a small percentage of the injected dose accumulates in the tumor,
which most the nanoparticles accumulating in the liver and spleen.
It is hypothesized that combining the acoustic activity of an ultrasound contrast
iii
agent with the high payload and extravasation ability of a nanoparticle, localized de-
livery to the tumor with reduced systemic toxicity can be achieved. This method
can be accomplished by either loading nanoparticles onto the shell of the microbubble
or through a coadministration method of both nanoparticles and microbubbles. The
work presented in this dissertation utilizes novel and commercial nanoparticle formu-
lations, combined with microbubbles and a variety of ultrasound systems. Ultrasound
parameters are optimized to achieve maximum cell internalization of molecules and
increased nanoparticle delivery to a cell layer on a coverslip. In vivo studies demon-
strate the possibility of using a lower dose of paclitaxel to slow tumor growth rates,
increase doxorubicin concentration in tumor tissue, and enhance tumor delivery of fluo-
rescent molecules through treatments that combine nanoparticles with ultrasound and
microbubbles.
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CHAPTER 1
Introduction
Ultrasound (US) imaging is one of the most widely used imaging modalities in the
clinical setting. It is safe (does not use ionizing radiation), inexpensive, and portable.
Ultrasound can be used as a primary diagnostic tool or in combinations with other
modalities and procedures, such as with an ultrasound guided needle biopsy. While
most individuals are familiar with the role of ultrasound in obstetrics and echocar-
diography, the capabilities of ultrasound reach far beyond those fields. Interestingly,
ultrasound can be used both for diagnostic imaging and for therapy. In recent decades,
the field of therapeutic ultrasound has made great progress with developments in both
preclinical and clinical settings aided by the use of microbubble contrast agents.
1.1 Ultrasound and Microbubble Contrast Agents
Approved for use in echocardiography, microbubble contrast agents (MCA) are en-
capsulated gaseous microspheres that improve the quality of ultrasound images as a
result of the difference in acoustic impedance between their gaseous core and the sur-
rounding medium (blood) and because of their nonlinear oscillation in an acoustic field
[1; 2; 3; 4; 5]. With diameters ranging from 1-10 microns, microbubbles are composed
c©2013 IEEE. Portions reprinted, with permission, from LB Mullin, LC Phillips, PA Dayton,
“Nanoparticle delivery enhancement with acoustically activated microbubbles,” IEEE Trans Ultrason
Ferroelectr Freq Control, 2013; 60(1): 65-77.
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of a protein, polymer, or lipid shell layer, and a gas core filled with a high molecular
weight gas such as a perfluorocarbon or sulfur hexafluoride (Figure 1.1) [6].
Figure 1.1: Microbubbles are composed of a gas core and stabilizing shell, such as a
lipid layer. Polyethylene glycol (PEG) adds stability and reduces bubble aggregate
formation.
Microbubbles have been utilized for imaging myocardial perfusion [7; 8]; left ven-
tricular opacification [9; 10]; blood perfusion in tumors [11; 12], livers [13], and kidneys
[14]; and for molecular targeting of angiogenesis [15; 16] or inflammation [17; 18; 19]. In
recent years, the use of ultrasound microbubble contrast agents has expanded beyond
their primary role in diagnostics and into the research fields of drug and gene therapy
[1; 5; 2; 3].
1.1.1 History of Contrast Agent Development
The ability of an injected microbubble to improve ultrasound image quality was
first described in 1968 by Gramiak and Shah [20]. Agitated saline air microbubbles
improved left ventricular cardiac imaging in patients; however, these air bubbles had
very limited circulation times. It was realized that by modifying the properties of
microbubbles, circulation time could be increased. Microbubble encapsulation was
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developed to prolong circulation lifetime of the bubbles. First generation contrast
agents, Albunex microbubbles, were composed of a serum albumin shell and air core.
Optison was later developed with a perfluorocarbon gas core. The incorporation of
a higher molecular weight gas prolonged circulation as the modified gas core diffuses
slower through the shell compared to air. Another important feature of microbubbles
is the incorporation of polyethylene glycol (PEG), which prevents bubble aggregation
and helps to avoid being phagocytosed while circulating. Definity, which is the contrast
agent currently approved by the Food and Drug Administration (FDA) consists of a
lipid shell and perflurocarbon gas core. Other agents, such as SonoVue (Bracco) are
in use throughout the world, but are not approved in the United States. Additionally,
many research groups, including our own, manufacture their own contrast agents for
research purposes.
1.1.2 Response of Microbubble Contrast Agents to Ultrasound
Image Quality Improvement
The gas core effectively reflects sound waves due to the differences in impedance (a
property based on density and the speed of sound) between the gas core and surrounding
tissue and blood. Additionally, the compressibility of the microbubble due to the shell
creates a nonlinear response of the microbubble as it expands and contracts within
the ultrasound field. This nonlinear response produces harmonic signals that can be
detected by ultrasound systems allowing contrast imaging to be a powerful clinical tool.
Cavitation and Microbubble Destruction
Exposure to higher amplitude signals leads to microbubble cavitation and/or even-
tual microbubble destruction. Cavitation can be either stable or inertial. In stable
cavitation, the microbubble will oscillate without rupturing. In ineritial cavitation the
the microbubble will expand more than it contracts, leading to violent collapse of the
3
microbubble. As a result, the microbubble may fragment and dissociate. Microbubble
destruction can lead to changes in cellular and vascular permeability. The process of
causing pore formation in cells is known as sonoporation, explored in Chapters 2 and
3.
Radiation Force
Acoustic radiation force, or the Bjerknes force, refers to the directional force ex-
perienced by objects in an ultrasound field. Microbubbles can be translated in the
direction of the acoustic wave propagation due to the transfer of momentum from the
sound wave to the bubble [21; 22]. In order to achieve translation, radiation force pulse
sequences require a high duty cycle which is low in amplitude so as to not rupture the
microbubbles. Radiation force applied perpendicularly to vessel orientation can result
in microbubbles being pushed to the vessel walls, where they can accumulate [23].
This use of radiation force can be applied to many areas of ultrasound including
molecular imaging [24; 25], drug delivery [26], in addition to the field of elastography to
determine properties of tissues [27]. When applied to microbubbles, acoustic radiation
force has been shown to increase the number of microbubbles present at a target site
by up to a 100 fold compared to without radiation force in vitro [28], and up to 20 fold
increase in vivo [29].
1.2 Cancer and Nanoparticles
1.2.1 Chemotherapeutic Drugs
Currently, cancer is the second leading cause of death in the United States [30].
While improvements to cancer detection and treatment have been made, there is still
a long way to go. The primary treatment options for cancer patients are surgery,
radiation treatment and chemotherapy. Often times a combination of these methods is
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used [31].
Traditional chemotherapy drugs attack rapidly dividing cells, meaning cancerous
as well as normal cells can be affected [32]. Hair loss, gastrointestinal issues, and
myelosuppression are common side effects seen with chemotherapy treatment; nausea
and vomiting are often cited as top distressing symptoms. These adverse effects can
lead to esophageal tears, fractures, malnutrition, acid-base and electrolyte changes and
patients’ refusal to continue chemotherapeutic cycles, which decrease patient quality of
life and compromises treatment efficacy [33].
There are many chemotherapeutics used in the clinic today, however, this research
will focus on drug formulations involving doxorubicin and paclitaxel. Paclitaxel is
most commonly used to treat lung, breast, ovarian cancer [34; 35]. One of the dose
limiting side effects of this class of drug is peripheral nerve damage. Doxorubicin, an
anthracycline, is an example of an anti-tumor antibiotic that interferes with enzymes
associated with DNA replication. While this class of drug is used to treat many cancer
types, cardiac damage is a concern for treatment [36]. Along with serious side effects
from chemotherapeutics, limitations of traditional chemotherapy drug include limited
solubility, lack of specificity and multidrug resistance [31; 37]. Ways to address these
limitations are discussed later in this chapter and throughout this dissertation.
1.2.2 Tumor Microenvironment
When a cancerous mass grows larger than 2 mm3, it can no longer get the oxygen
and nutrients it needs, and experiences hypoxia. The hypoxic state triggers the release
of numerous angiogenic factors such as VEGF-A (simply referred to as VEGF), fibrob-
last growth factor -2, angiopoietin 2, platelet derived growth factor, interleukin-8 and
chemokines [38; 39; 40; 41; 42]. Increased presence of these factors triggers a switch
to angiogenesis (new vessel formation) [43; 39; 41]. VEGF plays the primary role of
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mediating tumor angiogenesis by binding to vascular endothelial growth factor recep-
tor 2 (VEGF-2), which is presented on endothelial cells. Binding to the receptor starts
multiple signaling pathways leading to up-regulation of genes triggering proliferation
and migration of endothelial cells [42]. Vasodilation occurs along with an increase in
permeability of existing capillaries. This is followed by extravasation of plasma proteins
which provide the matrix for migrating endothelial cells [43; 39]. The TIE-2 receptor,
also expressed on the vascular endothelium is linked to the tyrosine kinase signaling
pathway. Angiopoioetin-1 and angiopoietin-2 bind to the TIE-2 receptor, signaling
loosening of the pericytes along the vessels [43]. When endothelial migration occurs, a
tip cell is selected and the neighboring cells (stalk cells) divide.
Vessels formed during tumor angiogenesis are abnormal in several ways. Tumor vas-
culature is disorganized, tortuous, dilated, and heterogeneous due to the imbalance of
pro- and anti-angiogenic factors present in tumors [38; 41]. Tumor blood flow can also
be an order of magnitude slower than in normal vasculature [38]. Tumor vasculature
is characterized by large inter-endothelial junctions, increased number of fenestrations
and abnormal basement membrane formation [38]. The endothelial cells recruited dur-
ing angiogenesis are also abnormal, with altered receptor activity, signaling pathways,
gene expression, and structure [44]. Pericytes are cells that in normal vasculature are
closely associated with vessels, providing stability. In tumor vessels however, fewer per-
icytes are present, and they are loosely associated, leading to gaps [42]. The decrease
in number and association of pericytes causes abnormal vessel diameters [43]. There
is also a lack of smooth muscle cells, which would help regulate blood flow in normal
vasculature [41]. Abnormalities continue to be seen in the basement membrane where
the collagen thickness and proximity to endothelial cells may vary [44]. Due to inad-
equate vessel formation, the tumor environment remains hypoxic, which can reduce
sensitivity to radiation treatment and other therapies, along with hinder the ability of
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immune cells [38]. The continued hypoxic state triggers VEGF and other factors from
tumor cells and recruited host cells (such as inflammatory cells), further promoting the
angiogenesis cycle [39].
Enhanced Permeability and Retention Effect
The abnormal characteristics of tumor angiogenesis contribute to what is known as
the enhanced permeability and retention (EPR) effect, first described by Matsumura
and Meada in 1986 [45]. Due to the leaky vessels and large fenestrations (from abnor-
malities described above), tumor vasculature is more permeable than healthy vessels.
The gaps or pores found in tumor vessels has been found to often range from 100 nm up
to 2 µm, depending on the tumor type and location [38]. Some reports have even cited
endothelial openings as large as 4.7 µm [46]. The enhanced retention comes from the
lack of lymphatic clearance in the tumor tissue. The lymphatic system within tumors
is nonfunctional (does not transport fluid or macromolecules) due to compression of
lymphatic vessels, which causes an increase in interstitial pressure. [38; 41].
1.2.3 Nanoparticles
These characteristics provide an environment that can be exploited by nanoparti-
cles. Although strictly defined by the National Cancer Institute as any particle with
at least one dimension under 100 nm, this dissertation will use the term nanoparticle
to describe any sub-micrometer vehicle. Nanoparticles are often capable of carrying
a therapeutic payload and vary in shape, size, and physical and therapeutic proper-
ties. Some common types of nanoparticles are micelles, liposomes, dendrimers, solid
nanoparticles, nanocapsules and emulsions [47; 48]. Nanoparticles can be easily mod-
ified to effect bioavailability, cytotoxicity, clearance and recognition by the immune
system [49]. Additional modifications can make nanoparticles multifunctional serv-
ing both therapeutic and diagnostic purposes with the capability to include multiple
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targeting ligands and drug combinations [50].
Nanoparticles are often used as delivery vehicles by encapsulating a therapeutic com-
pound that may otherwise cause systemic toxicity if delivered in free form. Nanoparticle
delivery vehicles show promise for carrying high therapeutic payloads, controllable re-
lease rates, and targeting abilities - both passive and active [48]. Passive targeting
refers to the uptake of particles based solely on their size. Active targeting involves
adding a component to the particle that will bind to a specific biological tag that is
overexpressed in the tumor such as integrins, folic acid, or antigens.
In cancer therapy, the small size of nanoparticles is particularly advantageous within
tumor vasculature. The EPR effect enables passive targeting of nanoparticle drugs to
tumors. The particles cannot pass through normal vasculature with endothelial junc-
tions of 5-10 nm, but accumulate within the tumor tissue through the leaky vasculature
[47]. This is significant because harmful side effects seen in traditional chemotherapy
can be greatly reduced. Nanoparticles ranging from 10-100 nm in size are ideal for
delivery to tumors. Being larger than 10 nm evades renal clearance, and under 100
nm avoids hepatic clearance [47]. The long circulation time is an important property
to allow the particle time to accumulate within the tumor. Polyethylene glycol (PEG)
on the surface of the particle helps to avoid the mononuclear phagocyte system and
thereby prolong circulation. Size is also a major determining property to not only
ensure extravasation, but to increase penetration into the tumor tissue.
Preclinically, there are countless formulations of chemotherapeutic nanoparticles
being investigated. Animal models provide the means for scientists to investigate the
impact of various nanoparticle characteristics on tumor delivery and effectiveness of
treatment. There are also several examples of passively targeted nanomedicines used
in the clinic, some of which are in clinical trials while other are approved for patient
use. Liposomes were the first nanoparticles to be approved for cancer therapy by the
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FDA [47]. Liposomes include Doxil, Myocet, DaunoXome, Onco-TCS, and Marquibo.
Myocet and Doxil are both liposome formulations of doxorubicin, however Doxil is
PEGylated. DaunoXome is PEGylated daunorubicin. Examples of other approved
nanoparticles include Abraxane- an albumin bound paclitaxel nanoparticle, Transdrug-
a doxorubicin nanoparticle, and Nanoxel- a paclitaxel nanoparticle. Despite the success
of these formulations, the translation of nanomedicine into the clinical setting has been
unexpectedly slow [51].
There are numerous factors that contribute to the limited clinical success of nanopar-
ticles for cancer therapy. Although nanoparticles may be able to exit through the leaky
vasculature of the tumor, there are still other barriers to delivery. The tumor microen-
vironment is composed of a matrix of collagen fibers, proteoglycans and glycosamino-
glycans, which can hinder nanoparticles from reaching tumor cells [51]. Nanoparticles
must travel through this matrix and enter into tumor cells must occur for chemother-
apeutics to have their full therapeutic effect.
Scientists have also observed an overestimation of the EPR effect in murine models
compared to human tumors. Rapidly growing tumors, such as subcutaneous tumor in
mice, produce large quantities of VEGF and other mediators which enhance perme-
ability effects [51; 52]. Heterogeneity within tumors and tumor types has also been
observed. Tumor location and host environment can also impact permeability. For
example, glioma tumors grown subcutaneously are more leaky than orthotopic tumors
[38].
Additionally, although nanoparticles do limit exposure of many healthy cells, they
still accumulate in other organs such as the liver and spleen. Studies have shown
that less than 5% of the injected dose accumulates in the tumor. These limitations
of nanoparticles in cancer therapy have lead researches to look of ways to improve
nanoparticle delivery into tumors.
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1.3 Scope
Combining ultrasound and microbubbles with nanoparticles has the potential to
overcome the limitations of current therapy practice for cancer, as well as many other
conditions. While the field of ultrasound mediated drug delivery has been expanding,
there are still many unknowns, and much room for improvement. This research aims
to optimize ultrasound and microbubble parameters to improve targeted nanoparticle
drug delivery. We hypothesize that improved chemotherapeutic delivery, with reduced
systemic toxicity, can be achieved by utilizing ultrasound to concentrate and disrupt
microbubble contrast agents at a target site in the presence of a nanoparticle drug.
This dissertation will present research on a variety of nanoparticle formulations, both
novel and commercially available, combined with the use of microbubbles and a variety
of ultrasound systems ranging from piston transducers to clinical scanners.
This chapter has introduced the importance of microbubble contrast agents and
nanoparticles. In Chapter 2, progress in the field of ultrasound mediated nanoparticle
drug delivery will be discussed further.
In Chapter 3, the ability of ultrasound to enhance local nanoparticle delivery in
vitro is explored. Acoustic parameters are optimized to enhance cellular internalization
of molecules through sonoporation. Microbubble parameters are also investigated to
achieve optimal internalization.
Chapter 4 will illustrate the combined effects of acoustic radiation force and mi-
crobubble destruction for targeted delivery in vitro. An acoustically active delivery
vehicle is created that is comprised of a microbubble coated in nanoparticles.
Chapter 5 demonstrates the potential of ultrasound as a therapeutic tool in vivo
through treatment of tumor bearing mice. Combined ultrasound treatment is compared
to nanoparticle only treatment.
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Chapter 6 describes preliminary studies conducted using nanoparticle-loaded mi-
crobubbles combined with acoustic radiation force and microbubble destruction. These
studies are carried out using a clinical ultrasound scanner to deliver nanoparticles within
tumors in preclinical cancer models.
In Chapter 7, pharmacokinetic analysis of nanoparticle drug delivery combined with
therapeutic ultrasound in a mouse breast cancer model is explored. Liposomal doxoru-
bicin treatment is compared to a co-injection of microbubbles and liposomal doxorubicin
combined with focused ultrasound treatment.
Chapter 8 will summarize the work presented in this dissertation and discuss the
limitations and challenges of ultrasound mediated drug delivery and the path towards
clinical translation.
Other work related to improving ultrasound imaging methods is present in the
appendix.
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CHAPTER 2
Ultrasound Drug Delivery
2.1 Introduction
Ultrasound is being explored as a platform for enhancing therapeutic delivery. Stud-
ies investigating gene and drug delivery aided by ultrasound are rapidly gaining popu-
larity. A subset of the drug delivery field focuses on nanoparticle delivery. This chapter
provides a more in depth explanation of the role of ultrasound and provides a review
of this body of literature.
2.2 Ultrasound and Nanoparticles
In the field of therapeutic ultrasound with microbubbles, the most commonly used
types of nanoparticles are quantum dots [53], liposomes [54; 55; 56; 57], and poly(lactic-
coglycolic acid) (PLGA) nanoparticles [58; 59]. Quantum dots are often used in studies
in place of nanoparticle drugs to characterize delivery vehicles and evaluate successful
delivery into targeted tissue. Doxorubicin-containing liposomes have been used exten-
sively in ultrasound and microbubble delivery studies (see Appendix A). One reason
for their popularity in research studies is that several forms, known as Doxil or Caelyx,
c©2013 IEEE. Portions reprinted, with permission, from LB Mullin, LC Philips, PA Dayton.
“Nanoparticle delivery enhancement with acoustically activated microbubbles” IEEE Trans Ultrason
Ferroelectr Freq Control, 2013; 60(1): 65-77.
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DaunoXome, and Myocet, are already FDA approved for clinical use. Doxorubicin is
also inherently fluorescent, which makes optical tracking of delivery feasible. Another
form of liposome used with microbubble ultrasound delivery is the lipoplex, which is a
liposome containing genetic material such as plasmid DNA [60; 61; 62]. This method
protects the DNA during in vivo circulation and allows a greater amount of genetic
material to be delivered [60; 61].
2.2.1 Mechanisms of Delivery
Ultrasound exposure in the presence of microbubbles can increase both cellular and
vascular permeability, leading to enhanced nanoparticle delivery. An increase in cell
permeability ensues from the formation of pores in the cell membrane during a process
called sonoporation. At higher pressures, ultrasound alone can cause the formation
of pores within the cell membrane [63]. This effect is enhanced with the addition of
microbubbles. Although the exact mechanisms are not fully understood, the oscillation
of microbubbles in an ultrasound field creates transient pores in the lipid bilayer [64;
65; 66]. The degree of sonoporation is dependent on the cavitation behavior of the
microbubbles, which is in turn dependent on the acoustic conditions applied. Both
stable and inertial cavitation have been shown to result in pore formation [1; 26]. During
stable cavitation, the microbubble oscillates without disruption, whereas during inertial
cavitation, the microbubble is unstable and fragments [1]. Streaming of fluid around the
bubble can occur in both cases and causes shearing of the cellular membrane [67; 68].
When microbubbles near cellular membranes are exposed to high-energy pulses, they
often form microjets during collapse, resulting in high shear stresses from streaming
and shockwaves that are thought to lead to pore formation [69; 70]. In addition to
creating openings in cells, the cavitation response of microbubbles may also facilitate
uptake by forcing the nanoparticles into the cell through microjets [71].
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Pore formation can be either transient (reversible) or permanent. Transient pore
formation has been observed in vitro, wherein pores remained open for seconds to hours.
In some instances, pore openings have been reported up to 24 h after ultrasound ex-
posure [72]. Permanent pore formation is undesirable in most applications, because it
leads to cell death. Consequently, care must be taken in selecting appropriate acoustic
conditions because cell death can occur with sufficiently high or long ultrasound ex-
posure [67; 68; 73]. For example, Deng et al. observed an increased transmembrane
current in cells subjected to both ultrasound and the presence of microbubbles indicat-
ing increased membrane porosity [74]. Cells recovered to resting levels in about 4 to 10
s following insonation for approximately 1 s at 1 MHz and 1 MPa pressure, but higher
ultrasound intensities (>1 MPa) for durations longer than 0.5 s resulted in irreversible
cell damage and cell death. In general, reagent delivery increases with increasing acous-
tic pressure, but so too does the likelihood of cell apoptosis [73; 74; 75; 76; 77].
Many groups are also investigating cellular changes that occur as a result of ul-
trasound exposure, including changes in calcium levels, cell signaling pathways, and
endocytosis [65; 78]. In a study on gene delivery to BLM melanoma cells, Lentacker et
al. found that lipoplexes were directly entering the cell cytoplasm through sonoporation
rather than endocytosis [61]. The uptake was seen to occur during or immediately after
ultrasound exposure. Meijering et al. also observed small molecules (4.4 and 70 kDa)
entering the cell membrane via pores, however they found that larger molecules (155
and 400 kDa) were entering into the cell through vesicle formation in endocytosis [65].
The role of calcium in sonoporation has been investigated and calcium is believed to
aid in cell recovery after pore formation [79]. Other cellular changes that have been ob-
served are hyperpolarization of the cell membrane, release of free radicals, and increased
levels of hydrogen peroxide [79; 80]. Yang et al. recorded differences in cell viability
and permeability depending on the stage of cell growth, indicating the cell cycle may
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play a role in cell permeability [79]. With respect to vessel permeability, effects can
range from mild reversible permeability enhancement to gross vessel rupture, depend-
ing on the microbubble and acoustic parameters [81; 82; 83; 84; 85]. Results from many
groups have suggested that large molecules (such as dextrans), as well as nanoparticles,
enter into the interstitial space after sonication with microbubbles [86; 87; 88; 89]. This
vascular permeability is expected to be a result of the interaction between microbubbles
and vessel walls. Caskey et al. studied the effects of insonated microbubbles within ex
vivo vessels and observed both asymmetric collapse and jet formation near the vessel
wall [90]. Chen et al. also studied microbubbles within ex vivo vessels and observed
that jet formation occurs away from the vessel wall [91; 92; 93].
Acoustic radiation force also enhances nanoparticle delivery. Radiation force, ex-
plained in Chapter 1, refers to the ability to push an object, such as a microbubble,
within an ultrasound field. When nanoparticles are attached to the microbubble, the lo-
cal concentration of nanoparticles can be increased by pushing the microbubbles against
the vessel wall in one location [23; 28; 94]. This phenomenon has been shown to aid in
delivery of nanoparticles when microbubbles are used [54; 95; 96; 97].
2.2.2 Types of Administration
There are two main administration methods employed for nanoparticle delivery
with ultrasound and microbubbles: unbound and bound nanoparticles. In the first
method, the nanoparticles are not associated with the microbubbles, but are either
injected separately or co-administered. If separate injections are performed, the order
of injection may vary as long as microbubbles are present when ultrasound is applied.
Lin et al. showed no significant difference in tumor accumulation between quantum
dot injection before or after insonation as long as microbubbles were present during
the ultrasound [98]. The second method of delivery requires the nanoparticles to be
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attached to the microbubble before injection and ultrasound treatment. There are
numerous ways to associate the nanoparticle with the microbubble. One of the most
common methods to attach a nanoparticle to the microbubble is with the use of biotin
avidin interactions.
Biotinylated microbubbles are used to attach either avidin or streptavidin nanopar-
ticles, or in some cases an avidin linker is used to link biotinylated particles [54; 57].
Although biotin avidin linkage is suitable for proof of concept studies, it is not ideal for
in vivo use because it can induce an immunogenic response [54; 99]. An alternative to
this method is to use maleimidethiol chemistry. Maleimide conjugation is often used in
molecular imaging studies to create targeted microbubbles and can also be applied to
nanoparticle attachment to the shell of the microbubble [56]. Another covalent binding
possibility was illustrated by Burke et al., in which PLGA nanoparticles were coupled
to albumin microbubbles through carbodiimide chemistry [58]. Oligonucleotides have
also been employed as tethers to link vesicles to microbubbles through hybridization of
complementary lipid-linked DNA oligonucleotides [100].
Electrostatic binding of nanoparticles to microbubbles is often implemented in gene
delivery studies, wherein negatively charged DNA is attached to positively charged
microbubbles with shells composed of a cationic lipid. Electrostatic interactions can
also be exploited to create nanoparticle-bound microbubbles. One example of this
was described by Seo et al. who created positively charged monodisperse microbubbles
through microfluidics and attached negatively charged silica-coated nanoparticles [101].
This technique was shown to be effective for various sizes and shapes of nanoparticles.
Drugs can also be directly incorporated into the shell of the microbubble, although
this provides a challenge in the inherently limited payload capacity. Drug-loaded
polymer-shelled microbubbles, whose thicker shells allow for higher drug loading, frag-
ment into nanoshards, which are less than 400 nm in size [102; 103; 104]. These shards
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are small enough to extravasate from the vasculature of the tumor.
There are some definite advantages to linking the nanoparticle to the microbubbles.
Along with being able to track the nanoparticle in circulation by ultrasound imaging
of the microbubble carriers, attaching the nanoparticle ensures that they are present
at the target site during insonation. Using ultrasound to rupture the microbubble at
a desired location leads to targeted deposition of particles. As discussed previously,
linking the nanoparticle to the microbubble also allows for radiation force to be used
to increase particle/drug concentration at the desired site. Lum et al. and Kheirolo-
moom et al. demonstrated higher delivery of nanoparticles in vitro using radiation
force in combination with microbubble-loaded nanoparticle constructs compared with
without using radiation force [95; 54]. Linking nanoparticles to microbubbles is also
advantageous because it prevents dilution of the nanoparticle solution when it enters
the bloodstream [58]. Finally, microbubbles loaded with certain nanoparticles may
serve as multi-modality contrast agents for platforms such as dual MRI-ultrasound and
optical-ultrasound [105; 106; 107].
There are also some challenges related to associating the nanoparticle to the shell.
When linking through a process such as biotin and avidin, multiple washing steps
are necessary to remove free linking agent. This can be both time consuming and
detrimental to the fragile bubble preparation, requiring a higher initial concentration
of microbubbles. Furthermore, excess nanoparticles are typically required to maximize
loading. Finally, attaching the nanoparticle to the microbubble may alter the in vivo
circulation time and biodistribution.
2.3 Ultrasound Setups
There are a variety of ultrasound systems in use to accomplish microbubble-aided
nanoparticle delivery. Many researchers use single-element transducers powered by
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arbitrary waveform generators and amplifiers, whereas others use commercial therapy
systems or even clinical imaging systems (see Appendix A). In [108], Seip et al. describe
ideal qualities of a therapy system, including the ability to both image and treat a
desired location to monitor delivery and release of the agent. The system should be
able to generate intensities and pulse sequences needed for microbubble delivery, deliver
focused energy deep within tissue to target a specific area, treat in an acceptable amount
of time, be incorporated into current treatment workflow, and be easy to use and set
up. Most therapeutic treatments involve ultrasound with a center frequency of around
1 MHz, which is much lower than clinical imaging systems typically provide. Although
some custom systems have been created, dual imaging and treatment often requires
multiple transducers to be used in conjunction with one another [109]. Nanoparticle
delivery has been performed with both focused and unfocused transducers, as well as
at varying pressures up to 7 MPa.
2.4 Review of Successful Nanoparticle Delivery Studies
Some of the first nanoparticle delivery studies were performed in vivo with fluo-
rescent nano/microspheres (100 to 500 nm) delivered to rat skeletal muscle [86; 110].
In these studies, vessel rupture caused by microbubble breaking was observed and the
particles were delivered into the intersitium of the muscle. Extravasation points were
observed where particles and red blood cells leaked out of the vasculature. Findings also
illustrated the importance of allowing microbubbles to replenish in between ultrasound
pulses and quick (10 s) injection of particles to increase deposition. Delivery of fluores-
cent nanospheres (30 to 120 nm) to cardiac muscle was later shown by Vancraeynest
et al. [87].
The feasibility of in vivo nanoparticle drug delivery with microbubbles and ul-
trasound was demonstrated using PLGA nanoparticles loaded with fibroblast growth
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factor-2 [111]. Initial studies depicted 40-fold and 670-fold increases in nanoparticle de-
livery to the mouse adductor muscle when ultrasound or ultrasound and microbubbles
were applied compared with nanoparticles alone. Subsequently, drug- loaded nanopar-
ticles were delivered into the ischemic hind limb of the mouse with the addition of
ultrasound and microbubbles. Results of the studies showed an increase in total num-
ber of large and moderate diameter arterioles, as well as marked luminal expansion of
pre-existing collateral arteries and transverse arterioles. Although the growth factor
did not induce angiogenesis in gracilis muscles, arteriogenic remodeling was seen along
with an increase in arteriole-line intersections.
Successful nanoparticle gene delivery was demonstrated in vitro with plasmid DNA
(pDNA), short interfering RNA (siRNA) and messenger RNA (mRNA), often involving
a fluorescently tagged gene so that transfection can be easily quantified [60; 61; 62;
112; 113]. Encapsulating the genetic material within a liposome, creating a lipoplex, or
siPlex, protects the genetic material and allows more to be delivered to the target site.
Ultrasound-mediated delivery with microbubbles was found to overcome the limitations
of PEGylated liposomes. Although PEG increases circulation of the lipo/siPlexes, it
hinders cellular uptake. When cells in an Opticell were exposed to ultrasound, liposomes
loaded with up to 15 mol% PEG had limited gene expression/ inhibition with free
liposomes, but exposure to loaded microbubbles and ultrasound led to statistically
significant differences. These studies also demonstrated the direct entry of liposomes
into the cytoplasm when ultrasound and microbubbles are present [61]. Uptake and
expression were investigated further with mRNA lipoplexes loaded onto microbubbles
[62]. Uptake was observed in 50% of the cells when loaded microbubbles and ultrasound
were applied, compared with 0% uptake with lipoplexes alone, and 24% of the cells
illustrated successful transfection. These results support the hypothesis that not all of
the contents are released from liposomes upon insonation.
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Liposomal-loaded microbubbles have also proven to be advantageous for drug de-
livery. As mentioned in an earlier section, Doxil, and other doxorubicin-containing
liposomes are commonly used in ultrasound and microbubble delivery studies. When
doxorubicin-containing liposomes were bound to microbubbles and delivered to melanoma
cells in an Opticell, significantly higher cytotoxicity was seen [114]. Additional find-
ings indicated that enhanced delivery was caused by both release of doxorubicin from
liposomes and sonoporation caused by the microbubbles. The released free doxorubicin
enters into the cell more efficiently than the liposome-contained doxorubicin. Studies
carried out with self-assembling liposome-loaded microbubbles revealed a lower dose of
doxorubicin could be used when the liposomes were bound compared with free lipo-
somes [56].
Recently, enhanced in vivo delivery of liposomal doxorubicin has also been ob-
served. After several studies with lipid-coated quantum dots delivered in mice, studies
were carried out with Doxil and microbubbles with ultrasound exposure [115]. The
concentration of Doxil in tumor tissue over time, the impact on tumor size on various
treatments, and dose were investigated. Using focused ultrasound, more Doxil was
delivered when microbubbles were administered, and colorectal adenocarcinoma tumor
growth in mice was hindered. At 24 h after treatment, more drug was concentrated
within the tumor compared with treatments of Doxil alone, however, the concentra-
tions of both treatments were similar by 48 h. It was also observed that smaller tumors
responded better to treatment than larger tumors at 5 mg/kg. Larger tumors required
a higher treatment dose of 10 mg/kg. Tumor histology revealed extravasation of fluo-
rescent Doxil.
Delivery of doxorubicin-containing nanoshards has also been carried out in vivo.
Polymer microbubbles containing doxorubicin in the shell were destroyed within VX2
tumor-bearing rabbits, which created nanoshards capable of extravasating into tumor
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tissues. Initial studies revealed significantly higher concentration of doxorubicin within
the periphery of the tumor following ultrasound treatment compared with no insonation
[104]. In later work, significant differences in tumor growth were also observed between
mice treated with drug-loaded microbubbles and ultrasound compared with free drug at
14 days [116]. Paclitaxel-loaded polymer microbubbles are also being developed which
can hold up to 20 times as much drug as doxorubicin-loaded microbubbles [102].
Nanoparticle drug delivery has also recently been applied to fields outside of chemother-
apy [117]. Microbubbles loaded with rapamycin-coated magnetic ion nanoparticles are
being investigated as a treatment option for ischemic coronary heart disease. Using
magnetic stents, the nanoparticle-loaded microbubbles are targeted to the desired lo-
cation, and then the drug is released when the microbubbles are ruptured using ul-
trasound. In vitro studies have shown cell growth inhibition with rapamycin-loaded
nanoparticles, whereas testing of the magnetic stents confirms microbubble accumu-
lation at the stent. Increasing the flow conditions lead to an increase in nanoparticle
deposition.
2.5 Summary
In this chapter, the concept of combining ultrasound with nanoparticles for targeted
drug delivery was explored. Future chapters will focus on studies to improve these
methods by obtaining a better understanding of the role of the ultrasound settings and
microbubbles to increase permeability to enhance nanoparticle delivery to cells and
tumor tissues.
21
CHAPTER 3
Ultrasound and Microbubble Parameters for Maximizing Sonoporation
3.1 Introduction
Ultrasound mediated drug delivery can utilize various ultrasound techniques to
achieve enhanced delivery. Combining acoustic radiation force with microbubbles de-
struction has the potential to increase concentrations of therapeutics at the target site
when the therapeutic load is combined with the microbubble [26; 95; 96]. This method
uses radiation force to translate microbubbles to the targeted vessel walls followed by
destruction of the microbubbles close to the cells creates desirable bioeffects which
enhance delivery, such as pore formation.
Although increased permeability has been observed by many researchers, the mecha-
nisms behind sonoporation are not yet fully understood and are still being investigated.
Evidence would suggest, however, that microbubble cavitation plays an important role
in sonoporation. Both stable and inertial cavitation can result in pore formation [26; 1].
In stable cavitation, the microbubble gently oscillates, whereas in inertial cavitation the
microbubble violently collapses. Possible mechanisms leading to pore formation are mi-
crojets, streaming, and shear force [69; 70; 118]. In addition, changes in calcium levels,
cell signaling pathways and endocytosis have also been observed [65; 78; 119].
Along with the mechanisms leading to pore formation, there are other factors re-
lated to sonoporation that are also being studied. It is known that various ultrasound
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settings can affect delivery into cells. Frequency, duty cycle, and pressure are three fac-
tors which have been shown to impact sonoporation [65; 120; 121; 122; 73; 123; 124].
Microbubble composition is another important factor to consider when optimizing de-
livery. Microbubbles can be made with various shell and gas core components, and
the size can be altered through a number of techniques including centrifugation and
microfluidics [6]. The effect of microbubble size has been shown in imaging studies as
well as blood brain barrier delivery studies [83; 24]. Larger microbubbles lead to greater
contrast in images and also demonstrate better efficiency at disrupting the blood brain
barrier. Too many microbubbles can cause a shadowing effect due to signal attenuation,
whereas too few microbubbles may not provide enough contrast to see the desired area.
Similarly, microbubble concentration may also play a role in efficacy of sonoporation
[125; 126; 127].
Although these parameters have been studied previously by various groups as listed
in the prior paragraph, to date no group has evaluated all of the parameters described
here with the same experimental system. Thus, variations in experimental setups make
it challenging to compare the effects of parameters across studies. Differences in cell
type, cell seeding method (single cell, cell suspension, or adhered cells), microbub-
ble properties, transducer orientation, and ultrasound parameters all contribute to
inconsistent results. The aim of this study was to optimize in vitro cellular uptake
by controlling parameter settings including cell-bubble exposure time, pulse repetition
frequency (PRF), acoustic pressure, microbubble size distribution, and microbubble
concentration. An in vitro setup containing an inverted monolayer of cells on a cov-
erslip positioned above an unfocused 1 MHz transducer was used. This setup allows
for microbubble flotation to produce bubble-cell proximity. Studies were performed
to determine which parameters had the greatest impact of cellular uptake of calcein
molecules in order to guide future in vitro and in vivo experiments.
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3.2 Materials and Methods
3.2.1 Cell Culture
A549 human non-small lung cancer cells were purchased from ATCC (CCL-185).
The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L
glucose supplemented with 10% fetal bovine serum and 1% antibiotic media at 5% CO2,
37◦C. Cell monolayers were cultured on acoustically transparent Thermanox coverslips
(Nunc, Thermo Fisher Scientific) until nearly confluent. Studies involving the effects
of cell density were performed by seeding coverslips at low cell density and selecting
them for use once cells reached the desired confluency. Cell confluency studies were
performed on days 1-5 after seeding on coverslips.
3.2.2 Microbubble Preparation
Microbubbles were prepared with 1,2 Distearoyl-sn-glycero-3-phosphocoline (DSPC)
and 1,2 Distearoyl-sn-Glycero-3-Phosphoethanolmine-N-Methoxy (Polyethylene glycol)-
2000 (DSPE-PEGK) purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) (9:1
molar ratio). Phosphate buffered saline (PBS) was added to the lipids to create a
concentration of 1 mM (1 mg/mL). Smaller microbubble solutions (mean diameter less
than 1 µm) were formed by flowing decafluorobutane through the dissolved lipid so-
lution and activated via mechanical agitation using a VialMix as previously described
[128]. Larger microbubbles (mean diameter greater than 1 µm ) were formed using a
sonic dismembrator for 10 seconds at 70% power in the presence of decafluorobutane,
which produced a microbubble solution that was then centrifuged at settings described
by Streeter et al. and Feshitan et al. to isolate desired populations of microbubbles
[24; 129]. An Accusizer 780A device (Particle Sizing Systems, Santa Barbara, CA) was
used to measure concentrations and size distributions of the microbubbles (Fig. 3.1).
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Figure 3.1: Microbubble size distributions re obtained using an Accusizer 780A device.
Microbubbles (circles) with a mean diameter of 0.79 µm, were used in all experiments
unless otherwise stated and are referred to as the 1 µm microbubble population. Larger
microbubbles around 2 µm (squares) and 4 µm (triangles), mean diameters of 1.6 and
3.6 µm, respectively, were used to study the effects of mic size on sonoporation.
3.2.3 Sonoporation Setup
Calcein, a fluorescent molecule which does not normally enter cells, was used to
monitor the effects of sonoporation. Calcein was dissolved in Dulbeccos phosphate
buffered saline (DPBS) at a concentration of 1 mg/mL. A 1 MHz, 1 inch diameter
unfocused transducer (Olympus-Panametrics) was positioned beneath a Bioflex tissue
culture plate (Flexcell, Hillsborough, NC), with coupling gel between the transducer
face and the bottom membrane of the well (Fig. 3.2A). Cell coated coverslips were
positioned face down on a stand-off within a well (Fig. 3.2B). A solution with 25 µL of
microbubbles mixed with 1 mL of calcein was added to the well beneath the coverslip.
The cells were incubated with the calcein-microbubble solution for 10 minutes before
being sonicated for 3 min. After ultrasound exposure, the coverslip was removed from
the well and washed in PBS for 2 min on a rotating platform to remove excess calcein.
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Figure 3.2: (A) The in vitro setup consisted of a 1 MHz transducer positioned under-
neath a six well plate with soft membrane bottom. (B) A standoff was positioned inside
the well to hold the cell coated coverslip above the microbubble-calcein solution.
The transducer was excited with 5-cycle sinusoidal pulses from an arbitrary wave-
form generator (AWG2021 Tektronix, Beaverton, OR) and a 55 dB RF amplifier (3200L,
ENI, Rochester, NY). An additional arbitrary waveform generator (33120A, Hewlett
Packard, Palo Alto, CA) was used to control the pulse repetition frequency (PRF).
Pressure values were measured with a needle hydrophone positioned 8 mm from the
face of the transducer in a water bath.
Ultrasound parameters tested included incubation time, pulse repetition frequency,
pressure, and number of repeated exposures. Table 3.1 and Table 3.2 display the pa-
rameters studied. Unless otherwise indicated, setting used were 10 minute incubation,
PRF of 150 kHz, and 300 kPa. Microbubble distributions with 2 and 4 µm diameters
were tested and concentrations between 6 x106 and 1x1010 MB/mL were also studied.
Additional examination of the role of cell confluency on sonoporation was performed
on coverslips with varying degrees of cell coverage. Control experiments were carried
out with calcein incubation followed by ultrasound exposure without microbubbles.
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Table 3.1: Summary of acoustic parameters investigated
Incubation 1 min 5 min 10 min 15 min
PRF 0.15 Hz 1.5 Hz 15 Hz 150 Hz
Pressure 150 kPa 310 kPa 850 kPa 1200 kPa
Repetitions 1 2 3
Table 3.2: Summary of microbubble parameters investigated
MB Concentration 1x1010 MB/mL 2.5x108 MB/mL 6x106 MB/mL
MB Size 1 µm 2 µm 4 µm
3.2.4 Image Analysis
Both bright field and fluorescent micrographs of the coverslip were acquired with
a fluorescent microscope (Olympus BX51). Multiple images were acquired for each
coverslip. Fluorescent images were acquired and compared by summing the pixels
within areas of intensities above the noise threshold using Metamorph Basic (Molecular
Devices, Sunnyvale, CA). The pixel counts for each image acquired were averaged to
obtain a quantitative value for fluorescence for each coverslip. Once individual averages
were obtained, coverslips for each parameter were averaged and normalized to the
baseline setting. Analysis of cell confluency studies was carried out with an in house
MATLAB script developed to segment cell borders and calculate cell count and area
covered per coverslip. A mask was created to only measure fluorescence in areas where
cells were present.
3.2.5 Statistical Analysis
Each of the 5 images taken on each coverslip were averaged for overall average value
of the coverslip. The coverslips average values were then averaged together for similar
settings. Settings were compared using a Student’s t-test with a Bonferroni correction.
Values of p<0.05 were considered significant.
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3.3 Results and Discussion
Finding the optimal ultrasound parameters for in vitro delivery using microbubbles
is an important step to improving drug delivery techniques. Although there are ad-
ditional challenges that will need to be overcome for in vivo studies, demonstrating
successful in vitro delivery provides promise for future work. Calcein was used as a
fluorescent drug marker because it does not enter into cells under normal conditions
and is easily detectable within cells. Other groups have also demonstrated that calcein
is an appropriate permeability tracer [125; 130; 131].
Increasing PRF did not lead to a consistent increase in calcein uptake (Fig. 3.3A).
This data suggests that sonoporation may require only a few acoustic pulses to occur,
and increasing the number of acoustic pulses has no further cumulative effect. It was
also stated by Rahim et al. that the first 10 cycles were the most important [124].
Additionally, Fan et al. found that shorter pulses were more effective than longer ones,
as they avoid unwanted translation [132]; this finding supports the use of short pulse
length. Other groups, however, have seen an increase in sonoporation with increasing
the duty cycle [122]. Unlike in these experiments, Pan et al. increased the duty cycle by
increasing pulse length instead of adjusting the PRF. These conflicting findings suggest
that variations in in vitro setups may contribute to variations in optimal settings. In a
static chamber like the one used in these experiments, PRF may not play as important
a role as it would when microbubbles are non-stationary as in a flow chamber or vertical
setup, or even in vivo.
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Incubation time was observed to result in greater sonoporation after 10 minutes
of incubation than 1 and 5 minutes, but was not statistically significant (Fig. 3.3B).
As with PRF, high variability was seen in the data. Incubation time was studied to
determine whether longer incubation times would lead to greater uptake through sono-
poration as microbubbles float into contact with the cells on the coverslip. Although
no statistically significant differences were seen, a longer incubation time of 10 min
was used since it has been shown that greater sonoporation effects occur when the
microbubble is in close proximity to the cell [133]. In reviewing similar studies, some
groups allow flotation time while other group immediately expose the cells to ultra-
sound after the addition of microbubbles. This is one example of the variations in
experimental design that need to be studied more in depth in future work.
Within the range of acoustic parameters tested, calcein internalization by target
cells increased with increasing acoustic pressure (Fig. 3.3C). An increasing linear trend
in fluorescence was observed. Uptake increased up to tenfold by changing pressure from
300 up to 1200 kPa. A Student’s t-test showed a significant increase in calcein uptake
from baseline settings when pressure was above 500 kPa (p<0.05), but no significant
differences were seen between the higher pressure groups. Increasing acoustic pressure
is an established method of increasing the effects of sonoporation [73; 125; 134]. These
results validate the current setup as similar trends to other groups are seen. These find-
ings correlate with other groups who have seen increased permeability with increased
pressure. At higher acoustic pressures cell detachment was seen; similar findings were
presented by Karshafian et al. in an Opticell setup [73]. Cell detachment and cell death
are seen to increase with increasing pressure. Finding a balance between permeability
and viability is an important step to achieve optimal delivery and will continue to be
studied.
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Calcein internalization also increased with repeated exposures of the cells to mi-
crobubbles and ultrasound (Fig. 3.3D). After undergoing 10 minutes of incubation
with calcein and microbubbles followed by 3 minutes of ultrasound, the cell coated
coverslip was transferred to a new well and incubation and insonation was repeated
either one or two more times. Uptake was increased almost fourfold by increasing ul-
trasound and microbubbles exposure from 1 to 3 repetitions. Both 2 and 3 repetitions
were statistically significant from only 1 exposure cycle (p<0.05), although they were
not statistically different from each other. Repeating the ultrasound exposure with
calcein and microbubbles two or three times increased cellular uptake compared to
a single exposure. Adding fresh microbubbles to the well was performed to simulate
flowing microbubbles in vivo. During an in vivo experiment targeted vasculature would
continually be exposed to microbubbles. Although repeated exposures resulted in an
increase in cell uptake, it is not as practical a solution for current setup due to the
extra handling of the coverslips leading to higher chances of damaging the cells. A
modified experimental setup involving a flow chamber, such as one used by Chen et al.,
would not have the same limitation and may be able to achieve a similar effect while
more accurately representing the in vivo environment, however acoustic radiation force
would need to be applied to push microbubbles next to the cells since the flotation
aspect is removed [135].
Due to the large variance in data for the acoustic parameters tested, cell density on
the coverslip was studied to determine if it was affecting sonoporation results. Cells were
insonated at varying confluency levels to look for a correlation between cell growth and
sonoporation. Previous work by Yang et al. found that cells in the stage of mitosis were
more susceptible to pore formation that other stages of cells growth [79]. However, with
the tested acoustic parameters, experiments with cell confluency and uptake revealed
no significant difference. A consistent percentage of cells affected by sonoporation was
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seen regardless of the area of coverslip coated by cells. At the baseline settings, roughly
15% of cell area showed uptake of calcein regardless of the confluency of the coverslip.
Figure 3.4: (A) Three concentrations of 1 µm microbubbles were tested at the baseline
ultrasound settings. Reducing the concentration from the initial stock concentration
produced significantly higher amounts of calcein uptake within the cells (N=7). (B)
Two larger microbubble populations, 2 µm and 4 µm were tested at the optimal 1 µm
concentration. The 4 µm microbubbles did not result in calcein uptake (N=6). Mean
and standard deviation of normalized pixel count above baseline are plotted; *p<0.05
Microbubble concentration was also observed to affect sonoporation efficiency. A
statistical difference was seen between the middle concentration tested and both the
high and low concentrations with 1 µm microbubbles (Fig. 3.4A). It was observed
that it was possible to have too many or too few microbubbles present, which lead to
a decrease in sonoporation. These findings correlate with permeability results found
by Karshafian et al. who saw similar curves with both Optison and Definity [126].
Increasing concentration enhanced microbubble-cell interaction to a point, after which
microbubble screening reduces the acoustic energy delivered to microbubbles close to
cells. Bright field images showed the presence of large microbubbles even after washing
when a high concentration was used. It was observed that the microbubbles were not
breaking and were coalescing to form larger bubbles when higher concentrations were
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used. Large bubble cluster formation was also reported by Meijering et al. [65]. Unlike
with the ultrasound parameters, current findings on concentration dependence are not
in agreement with work published by Rahim et al., who believed concentration was not
a critical factor and did not see significant changes when changing the concentration
[124]. Studies presented here used a higher concentration of microbubbles and had the
transducer placed below the cells, requiring the ultrasound to penetrate through the
microbubble layer at the cell surface. Positioning the transducer below the microbubble
and cell layer simulates an in vivo environment where the radiation force would be used
to push the microbubbles out of flow before microbubble destruction. The cell suspen-
sion setup used by Karshafian et al. also required the ultrasound waves to penetrate
through the solution of microbubbles and cells [126]. Effects of microbubble attenu-
ation in vivo have been seen in imaging studies, and results presented here suggest
attenuation resulting from high concentrations could be critical for therapeutic studies
[136]. Other concentration studies see an increase and then plateau [124; 125]. It is
hypothesized that this different behavior can be attributed to differences in ultrasound
parameters used such as longer pulse length and higher duty cycle, along with trans-
ducer placement as mentioned above. Additionally, although the aim is to investigate
concentration, it is possible that these studies did not explore a wide enough range in
concentrations to observe the same increasing, then decreasing trend. Differences in
reporting concentrations used such as volume added or percent volume cannot always
be compared due to these differences in stock concentrations. Because stock concentra-
tions of microbubbles vary from 1x1010 down to 1x108, even using undiluted samples
are not comparing the same volume.
Microbubbles can be produced in a range of sizes, such as around 1 µm in diam-
eter for Definity (Lantheus Medical Imaging North Billerica, MA, USA), to around 2
µm for SonoVue (Bracco International BV, Amsterdam, Netherlands). Several groups,
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including our own, also have developed methods to size isolate larger microbubbles
[24; 129]. Since not all microbubble solutions have the same size characteristics it is
important to understand the impact of size on ultrasound mediated therapy. A clear
dependence on both size and concentration for sonoporation was observed. When 1
and 2 µm microbubbles were tested at the same concentration, similar results were
seen. However, with microbubbles closer to 4 µm in diameter, cellular uptake was not
observed (Fig. 3.4B). The 4 µm microbubbles were investigated further and a sim-
ilar distribution in optimal concentrations was seen to the 1 µm microbubbles, only
shifted to a lower concentration (Fig. 3.5). Lowering the concentration, however, led
to calcein internalization. While other groups have examined the role of microbubble
concentration and brand [125; 126; 137] this study takes a more in depth look at size
by comparing microbubbles with the same composition and expanding the range of
concentrations. Although Alter et al. compared Optison, Sonozoid, and SonoVue at
various concentrations, the focus was on finding the agent that worked the best, not
on studying the effect of size [137]. In addition, they concluded that size had little
influence, which is not in agreement to current findings. Here, the larger microbubbles
performed poorly compared to smaller bubbles at the same settings. A lower concen-
tration was needed to enhance delivery into the cells. The effect of size has also be
documented by Choi et al. with blood brain barrier studies, who also found that size
does have an impact on delivery [83]. Future exploration on the optimal concentration
based on microbubble size with varying frequency is needed to take into account the
resonance frequency dependent response of microbubbles.
It has been pointed out here and by other groups that variations exist in in vitro
setups used to study the effects on ultrasound on cells [138]. Because of the goal to focus
on sonoporation effects that would occur after acoustic radiation force, it was important
to make sure microbubble flotation was present. Allowing space for the microbubbles
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Figure 3.5: (A) 4 µm microbubbles tested at the peak concentration for 1 µm microbub-
bles did not show the same enhanced sonoporation effect. At a lower concentration,
calcein uptake was seen using the 4 µm microbubbles. Mean and standard deviation
of normalized pixel count above baseline are plotted (N=6). *p<0.05
to become in contact with the cells allows for the cavitation effects of the microbubble
to be studied in depth separate from acoustic radiation force. This would not have been
possible using a cell suspension study or with cells cultured on the bottom of well plate.
Additionally, precise control over the concentration of microbubbles present at each
ultrasound treated site was needed. In an OptiCell, the concentration of microbubbles
can decrease over time as microbubbles are destroyed at each exposure site and large
amounts of microbubbles solutions must be used at one time. These reasons contributed
to the use of a coverslip setup. Modifications were made to improve upon a traditional
treatment within a well by using a FlexCell plate which has a soft membrane bottom
that leads to less attenuation and reflection than a hard bottomed culture plate, as
well as a plastic coverslip instead of glass [139]. However, it could be advantageous
to have a chamber that can be fully submerged in a water bath to eliminate the air
interface. Future studies will be performed with additional modifications to the setup
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that eliminates the air interface by creating a sealed chamber submerged in a water
bath. Additional future work will look more in depth at the relationship between size
and concentration with respect to ultrasound frequency and pressure.
3.4 Conclusions
Determining optimal ultrasound parameters for sonoporation is beneficial for future
studies involving drugs or macromolecules. Challenges for in vitro studies include
selecting parameters that will increase cell permeability, yet not irreversibly damage
or detach cells. The presented findings are in agreement with current literature in
that there are substantial changes in sonoporation efficiency depending on acoustic
parameters, yet additional evidence was observed that microbubble concentration and
size play a larger role than previously believed. These findings will help inform ongoing
and future studies as microbubble- mediated ultrasound therapies develop towards
clinical use and bring more attention to the importance of experimental design.
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CHAPTER 4
Design of Acoustically Active Nanocapsule Delivery Vehicles for
Ultrasound-Targeted Chemotherapy
4.1 Introduction
In the previous chapter, the roles of various acoustic and microbubble parameters in
enhancing cellular permeability were examined. In this chapter, microbubble destruc-
tion and microbubble translation by acoustic radiation force are combined. In addition,
the first nanoparticle loaded microbubble used for this research is introduced.
By utilizing an acoustically-active delivery vehicle (AADV), which combines the
acoustic activity of a microbubble with the high payload and extravasation ability of
nanoparticles, the limitations of current chemotherapy delivery methodologies can be
overcome. In this chapter the synthesis and characterization of AADVs and preliminary
results of in vitro delivery to cells are described.
c©2010 IEEE. Portions reprinted, from L Mullin, P Ma, S Wadhwa, L Peng, RJ Mumper, and PA
Dayton. “Design and Testing of Acoustically-Active Therapeutic Nanocapsule Delivery Vehicles for
Ultrasound-Targeted Chemotherapy.” 2010 IEEE International Ultrasonics Symposium Proceedings.
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4.2 Materials and Methods
4.2.1 Materials
DSPC, DSPE-PEG2K, and DSPE-PEG2K-Biotin were purchased from Avanti Po-
lar Lipids (Alabaster, AL). Additionally, 25-[N- [(7- nitro- 2- 1, 3- benzoxadiazol- 4
-yl) methyl]amino]-27- norcholesterol (25-NBD- cholesterol) and 1, 2 - dioleoyl- sn-
glycero- 3 -[(N-(5- amino-1-carboxypentyl) iminodiacetic acid)succinyl] (nickel salt)
(DGS-NTA(Ni)) in chloroform, were purchased from Avanti Polar Lipids. Inc. Strep-
tavidin protein (His-tag) was purchased from Abcam (Cambridge, MA). Green Fluo-
rescent Protein (His-tag) was purchased from Millipore (Billerica, MA).
4.2.2 Biotinylated Microbubble Preparation
Lipid solutions were formed using a 9:0.5:0.5 molar ratio of DSPC, DSPE-PEG2K,
DSPE-PEG2K-Biotin in a 90 mL solution of phosphate-buffered saline (Fisher Scien-
tific, Pittsburg, PA). Size isolated microbubbles were created using the method previ-
ously described by Feshitan et al. and Streeter et al. [129; 24]. Briefly, using a sonic
dismembrator (Model 500, Fisher Scientific, Hampton, NH) for 15 seconds at 70% power
in the presence of decafluorobutane (SynQuest Labs, Alachua, FL), microbubbles were
generated via acoustic emulsification and isolated with centrifugation. Concentrations
and size distributions of the microbubbles were obtained using a laser light obscuration
and scattering device (Accusizer 780A, Particle Sizing Systems, Santa Barbara, CA).
4.2.3 BTM Nanocapsule Preparation
Nanocapsules were made by warm water microemulsion methods as previously de-
scribed by Dong et al. [140; 141]. Miglyol 812 as the oil phase, Brij 78, Vitamin
E TPGS, and DOGS-Ni-NTA as the surfactants were weighed out into a 7 mL glass
vial. The vial was heated to 65◦C to melt the oil and surfactants while stirring, and
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then preheated deionized water was added to form the nanocapsules. The excess of
DOGS-Ni-NTA was removed by a Sepharose CL-4B column and the nanocapsules were
concentrated by rotary evaporator. The final GFP nanocapsule was formed by adding
his-streptavidin and his-GFP into the concentrated nanocapsules.
Paclitaxel containing nanocapsules were made in a similar method. The behenoyl-
paclitaxel conjugate was dissolved in ethanol and transferred to the vial containing
the oil and surfactant mixture. Residual ethanol was evaporated under a stream of
nitrogen gas, and then preheated deionized water was added to form the nanocapsules.
The excess of DOGS-Ni- NTA was removed by a Sepharose CL-4B column and the
nanocapsules were concentrated by rotary evaporator. The final behenoyl-paclitaxel
nanocapsule containing his-streptavidin was formed by adding his-streptavidin into the
concentrated nanocapsule suspension.
Figure 4.1: (A)DGS-NTA-Ni was incorporated in the shell of BTM nanocapsules.
(B)Four out of the six co-ordination sites of Ni are occupied by NTA while the two
remaining sites (shown as occupied by water molecules) are available for binding by
the his-tagged peptides. Figure provided by Saurabh Wadhwa.
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4.2.4 AADV Preparation
Acoustically-active delivery vehicles (AADVs) were created by incubating microbub-
bles and nanocapsules within a syringe and mixing on a rotating stand. Free nanocap-
sules were removed by either washing by flotation or centrifugation. Vehicles were
examined using fluorescence microscopy or high performance liquid chromatography
(HPLC) to assess binding. Control vehicles were made of fluorescent avidin polystyrene
beads (Spherotech, Lake Forest, IL) conjugated to biotin microbubbles.
4.2.5 Cell Culture
Rodent mammary adenocarcinoma cells (R3230), maintained in DMEM medium
(Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum and 1% peni-
cillin/streptomycin, were grown as a cell monolayer on Thermanox coverslips (Nalge
Nunc, Rochester, NY). Thermanox coverslips were used because they are nearly acous-
tically transparent.
4.2.6 In Vitro Delivery
A flow phantom setup was used to determine acoustic parameters required to both
concentrate microbubble vehicles and to fragment the microbubble (Fig. 4.2). Both
a water-immersion objective and a 2.25 MHz focused transducer (Olympus Panamet-
rics, Waltham, MA) were mutually focused with each other and on a 200 µm tube.
Microbubbles were pushed through the tube by a syringe pump. An arbitrary wave-
form generator allowed pulse sequences of varying frequency and amplitude to excite
the transducer. A high speed camera allowed the microbubbles to be visualized while
being exposed to ultrasound.
In vitro experiments were performed using a static chamber to test vehicle and
parameter settings (Fig. 4.3). The static chamber consisting of a transducer and cell
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Figure 4.2: A high speed camera and phantom setup with the microscope and trans-
ducer mutually focused on a 200 µm tube allowed microbubbles to be visualized while
being exposed to ultrasound.
plate in a water bath was used to test the ability of ultrasound to locally increase
nanoparticle delivery. Cells cultured on a coverslip were exposed to an AADV solution
and positioned in front of a focused 2.25 MHz focused transducer. The cells were
exposed to ultrasound for three minutes then washed in PBS before being examined.
Figure 4.3: A static chamber consisting of a transducer and cell plate in a water bath
was used to test the ability of ultrasound to locally increase nanoparticle delivery. Cells
cultured on a coverslip were exposed to a AADV solution and positioned in the focus
of a 2.25 MHz transducer.
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Table 4.1: Composition and physicochemical characteristics of BTM-Ni nanoparticles
(Provided by Lei Peng and Saurabh Wadhwa)
Parameters BTMNi Nanoparticles
Brij 78/Vit E TPGS/M812 /DGS-NTA-Ni (mg/mL) 3.5/1.5/2.5/0.1
Particle size ± S.D. 183.9 ±1.33
Polydispersity Index 0.026
Zeta potential ± S.D. -14.8 ± 11.3
Nickel content (ng/mg NP) 145.6 ± 19.53
Binding efficiency (Molar) (Ni:GFP) 1:12
GFP: Streptavidin (molar ratio) 1:1
4.2.7 Vehicle Drug Loading
Paclitaxel-loaded AADVs were analyzed to determine the amount of drug bound
to the bubbles. Increasing amounts of microbubbles were added to a fixed volume
of nanocapsules to obtain a loading curve. After a floatation wash was performed,
the bottom PBS layer and top bubble layer were separated for analysis. The behenoyl-
paclitaxel conjugate concentration in nanocapsule formulations was measured by HPLC
with an Inertsil ODS-3 column. The mobile phase consisted of a solvent mixture of
isopropyl alcohol, water and acetonitrile (35:5:60, v/v/v) at a flow rate of 1.0 mL/min.
The retention time of behenoyl-paclitaxel was about 9.5 min.
4.3 Results and Discussion
Successful conjugation of GFP/Streptavidin labeled BTM nanocapsules onto the
shell of biotinylated microbubbles was verified by fluorescence microscopy (BX51 Mi-
croscope, Olympus, Center Valley, Pa) (Fig. 4.4). Modifications of the BTM nanocap-
sules involving various fluorescent moieties including Cy3, bodipy, and Oregon green
paclitaxel were also tested but could not be easily detected under the microscope.
Using a high speed camera, the response of microbubbles within a tube to various
ultrasound parameters was studied. Optimized radiation force was achieved with a
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Figure 4.4: (A) A cartoon illustration of proposed loading of nanocapsules onto the shell
of the microbubble. (B) Confirmation of loading onto the bubble seen by fluorescence
microscopy. c©2010 IEEE.
2.25 MHz focused transducer operated at 3.5 MHz, 50 kPa. Microbubble destruction
occurred with a 5 pulse sequence at 1.5 MHz, 1.2 MPa with 0.1 second pause between
each pulse. The final wavelength was a 3 second waveform operated at PRF of 150
mHz at a duty cycle of 30%.
In vitro static chamber experiments using the optimized parameters yielded higher
delivery of nanoparticles within the focus of the transducer compared to outside of the
focus (Fig. 4.5A). Using intensity thresholding in MetaMorph Basic software (Molecular
Devices, Downingtown, PA), comparisons were made for the amount of fluorescence
present in various areas of the coverslip. The relative integrated intensity shows a
14-fold increase in nanoparticle delivery within the focus of the ultrasound (Fig. 4.5B).
After optical confirmation of nanoparticles binding to the bubbles was seen, a quan-
titative analysis of the AADV was desired to determine the drug concentration delivered
to the cells was performed. HPLC results showed that an average of 50% of the initial
paclitaxel mixed with microbubbles was bound to the shell (Fig. 4.6). Nearly 80% of
43
the paclitaxel was recovered between the top bubble cake and bottom wash layer. It
is possible that there was more bound paclitaxel than detected due to loss during the
transferring process. Future work will include further drug load characterization of the
AADVs followed by in vitro drug cell uptake studies.
4.4 Conclusions
Binding of nanocapsules to ultrasound microbubble contrast agents was achieved
and the ability to increase delivery of nanocapsules using acoustic radiation force and
microbubble destruction by ultrasound was demonstrated. Fourteen times as many
particles were delivered to cells treated with ultrasound compared to untreated. Future
work will include studies with paclitaxel-loaded nanocapsules used both in vitro and
in vivo.
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Figure 4.5: A) Increased delivery of nanoparticles to cells was seen with exposure
to ultrasound. Images obtained with fluorescence microscopy show higher levels of
fluorescence associated with cells in the center of the disc (within the ultrasound focus)
compared to outside of the ultrasound focus. B) The relative integrated intensity shows
a 14 fold increase in nanoparticle delivery within the focus of the ultrasound.
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Figure 4.6: HPLC analysis of microbubble solutions containing paclitaxel nanocapsules
showed 50% binding of nanocapsules could be achieved. Mean values and standard
deviation are plotted; N=3. c©2010 IEEE.
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CHAPTER 5
4T1 Tumor Treatment with Paclitaxel Nanocapsules and Microbubble
Enhanced Ultrasound Delivery
5.1 Introduction
Nanoparticle based drug delivery is a rapidly growing field, especially in chemother-
apy applications. Nanoparticulate formulations offer a promising alternative to con-
ventional methods due to their size and high payload [142; 143; 47]. One reason for
the success of this technique is the enhanced permeability and retention (EPR) effect.
Nanoparticles can enter into the tumor through the leaky vasculature, thus delivering
higher doses of drugs to tumor tissue with lower systemic toxicity. BTM paclitaxel
nanocapsules (introduced in the previous chapter) are formed by oil and water mi-
croemulsion methods and overcome the limitations of poor drug solubility. This formu-
lation has previously been shown to be more effective at treating tumors in mice than
intravenous injections of Taxol [140; 141]. However, accumulation within the tumor
was still limited.
It is hypothesized that the addition of low intensity ultrasound and microbubbles
to a nanoparticle chemotherapeutic treatment will improve the overall efficacy of the
c© 2011 IEEE. Portions reprinted, with permission, from L Mullin, P Ma, K Johnson, RJ Mumper,
and PA Dayton. “Tumor Treatment with Microbubble Enhanced Low- Intensity Ultrasound and Pa-
clitaxel Nanocapsules Reduces Drug Dose Required for Therapeutic Effect.” 2011 IEEE International
Ultrasonics Symposium Proceedings
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treatment. Applying ultrasound at the tumor site may enhance nanoparticle drug
uptake by increasing vascular permeability through ultrasound targeted microbubble
destruction.
5.2 Materials and Methods
5.2.1 Materials
DSPC and DSPE-PEG2K were purchased from Avanti Polar Lipids (Alabaster, AL).
Paclitaxel was obtained from ScinoPharm Taiwan Ltd. Polyoxyl 20-stearyl ether (Brij
78) was obtained from Uniqema (Wilmington, DE). Vitamin E TPGS was generously
provided by Eastman Chemical Co. (Kingsport, TN). Behenoyl chloride was purchased
from Sigma-Aldrich (St. Luis, MO).
5.2.2 Microbubble Preparation
A lipid mixture (DSPC and DSPE- PEG2K) was prepared using a 9:1 molar ra-
tio, similar to a previously described method [128]. Briefly, lipids were dissolved in
chloroform, dried and dissolved into a buffer solution of PBS. The lipid solution was
then transferred into vials, which were then evacuated and filled with decafluorobutane
gas. Vials were shaken with a Vialmix shaker (Bristol-Myers Squibb Medical Imaging,
North Billerica, MA, USA) for 45 s prior to injection.
5.2.3 Nanocapsule Preparation
2’-behenoyl-paclitaxel (C22-PX) conjugate was synthesized using behenoyl chloride
and paclitaxel (PX) via a one-step esterification reaction. The synthesized conjugate
was confirmed and characterized by nuclear magnetic resonance, mass spectrometry,
and thin layer chromatography analysis. To prepare the C22-PX nanocapsules, briefly,
2.6 mg of Miglyol 812 as the oil phase, 2.0 mg of Brij 78, and 1.6 mg of Vitamin E
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TPGS as the surfactants were accurately weighed out into a 7 mL glass vial. The
vial was heated to 65◦C to melt the oil and surfactants while stirring. The C22-PX
in ethanol stock solution was transferred to the vial containing the oil and surfactant
mixture. Residual ethanol was evaporated under a stream of nitrogen gas, and then
preheated deionized water was added to obtain a final volume of 1 mL. Oil-in-water
microemulsions formed spontaneously at this elevated temperature and upon direct
cooling of the warm microemulsions to room temperature, nanocapsules formulations
were formed. To enhance circulation time, the Brij78PEG750 was synthesized and
incorporated on the surface of the nanocapsules.
Figure 5.1: Chemical Structure of the paclitaxel conjugate used. Figure provided by
Ping Ma.
5.2.4 Animal Preparation
Animals were handled according to National Institute of Health guidelines and our
study protocol was approved by the UNC Institutional Animal Care and Use Com-
mittee. Twenty four female BALB/c mice received a subcutaneous injection of 1x108
4T1 mammary carcinoma cells on the left flank. Treatment began once tumor volumes
reached approximately 100 mm3, about 1 week after injection.
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5.2.5 Treatment
Mice were divided into three treatment groups. Group one received a 200 µL tail
vein injection of C22-PX nanocapsules (NC). Group two received a 200 µL tail vein
injection of C22- PX nanocapsules followed by ultrasound exposure (NC+US). Group
three received a co-administration of 150 µL of C22- PX nanocapsules with 50 µL MB
followed by ultrasound exposure (NC+MB+US). The paclitaxel dose for all animals
was 2.5 mg/kg. After receiving the appropriate tail vein injection, animals were placed
on a heating pad and anesthetized with inhaled isoflurane at 1.5% through a nose cone.
Ultrasound gel was then applied between the tumor and the transducer. Therapeutic
ultrasound was applied with a Sonicator 740 system (Mettler Electronics Corp.). The
1 MHz transducer was operated at 2 W/cm2 and 10% duty cycle (Fig. 5.2). Tumors
were sonicated for two minutes. Treatments were given every other day for two weeks.
Figure 5.2: Therapeutic ultrasound was applied with a Sonicator 740 system (Mettler
Electronics Corp.). The 1 MHz transducer was operated at 2 W/cm2 and 10% duty
cycle. Tumors were sonicated for two minutes. Treatments were given every other day
for two weeks.
50
5.2.6 Analysis
Caliper measurements were taken every other day to measure the volume of the
tumor. The tumor size was calculated as 1/2 x (width)2 x (length). Animal weight was
also monitored.
After humanely sacrificing the mice, the tumors were removed and processed rou-
tinely for histology. Specifically, tissues were processed into paraffin and 5 µm sections
were stained with hematoxylin and eosin using standard methods. The histology slides
were scanned with an Olympus BX51 microscope and motorized 2-dimensional stage
controlled by MetaMorph software (Molecular Devices, Sunnyvale, CA). The digital
images were imported into ImageJ (NIH, Bethesda, MD). A color deconvolution algo-
rithm was performed on each digital histological image to separate the hematoxylin and
eosin [13]. An index was calculated by dividing the number of pixels that corresponded
to hematoxylin by the sum of the pixels that corresponded to hematoxylin and eosin.
5.3 Results and Discussion
Although tumor growth was not halted by any of the treatments, mice treated with
the combination of paclitaxel nanocapsules, microbubbles and ultrasound had slower
tumor growth compared to nanocapsules alone and nanocapsules with the addition of
ultrasound (Fig. 5.3). On days two, four, six, eight and twelve, there were signifi-
cant differences between average tumor volume between tumors treated nanocapsules
and ultrasound compared to nanocapsules, ultrasound and microbubbles (p<0.05). On
days six and ten, significant differences were seen between average tumor volume of
mice treated with nanocapsules only compared to nanocapsules, ultrasound and mi-
crobubbles (p<0.05). At the end of the two week treatment schedule, average volume
between all groups were not statistically different.
Previous work evaluated the efficacy of C22- PX nanocapsules at a dose equivalent
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Figure 5.3: Mice bearing 4T1 tumors were treated with either NC (N=8), NC and US
(N=8), or NC, MB, and US (N=6). Mice treated with nanocapsules, microbubbles and
ultrasound had the slowest tumor growth rates. Treatments days are marked by red
arrows; The treatment dose was 2.5 mg/kg of C22-PX nanocapsules. *Significant dif-
ference (p<0.05) between NC+US and NC+MB+US **Significant difference (p<0.05)
between NC and NC+MB+US. c© 2011 IEEE
to 5 mg/kg paclitaxel [144]. The results from this study were used to make a comparison
to our current study were the dose was lowered to 2.5 mg/kg. It was hypothesized that
the addition of ultrasound and microbubble will allow for a lower treatment dose to be
given. Because the tumors implants and treatments were done at separate times, the
tumor volume data was normalized to the starting volume. This lead to the finding
that the growth curve of tumors treated at the lower dose of 2.5 mg/kg with ultrasound
and microbubbles was similar to the growth curve produced at double the dose (Fig.
5.4). Hematoxylin and eosin staining of tumor tissue was performed to characterize any
differences in tissue based on treatment groups. Tumor samples all revealed necrotic
centers of the tumor, and no significant differences in areas of necrotic tissue between
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treatment groups (Fig. 5.5). Tumors were also harvested from animals that did not
receive any treatment.
Figure 5.4: Mice bearing 4T1 tumors were treated with either NC, NC and US, or NC,
MB, and US treated at 2.5 mg/kg were compared with data from unpublished work by
Ping Ma. Data was normalized to tumor starting volume. Mice treated with nanocap-
sules, microbubbles and ultrasound had the slowest tumor growth rates. Treatments
days are marked by red arrows. *Significant difference (p<0.05) between NC+US and
NC+MB+US **Significant difference (p<0.05) between NC and NC+MB+US. c© 2011
IEEE
Data indicated significant differences in tumor growth over treatment days, despite
the fact that the tumor used was an aggressive, quickly growing tumor. The study
design may be improved upon by using a higher treatment dose or by changing the
treatment schedule. Treating every other day with tail vein injections is difficult, and
the number of animals in the third treatment group decreased from eight to six because
it was not possible to do injections in two of the mice after a week of treatment.
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Figure 5.5: Mice were sacrificed after 14 days and tumors were harvested, sectioned
and stained using hematoxylin and eosin. Examples of tumor sections showing necrosis
in all treatment groups are shown.
5.4 Conclusions
Preliminary results showed the potential to reduce growth of an aggressive tumor
model using paclitaxel nanocapsules combined with microbubbles and ultrasound. The
combination of paclitaxel nanocapsules with microbubbles and ultrasound performed
equally as well as nanocapsules alone at twice the dose. It is hypothesized that further
optimization of ultrasound parameters and delivery vehicles may result in even greater
improvements in therapeutic effect. Future work will be done with nanocapsules linked
to the microbubble instead of a co-injection in an effort to deliver more drug to the
tumor.
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CHAPTER 6
In Vivo Targeted Nanoparticle Delivery to Tumors with Acoustic
Radiation Force
6.1 Introduction
In this chapter, a fluorescent AADV is used to investigate the ability of a clinical ul-
trasound scanner to enhance in vivo delivery of nanoparticles to tumors. As explained
in previous chapters, attaching nanoparticles onto the lipid shell of a microbubble al-
lows for both acoustic radiation force (ARF) and microbubble destruction to be used to
increase nanoparticle delivery. In chapter 4, enhanced delivery of fluorescent nanopar-
ticles to a cell layer was observed. Other groups have also demonstrated improved
delivery either to cells or tumor tissues by using a nanoparticle loaded microbubble
[145; 121; 113; 61; 95; 54]. An additional benefit of attaching the nanoparticle to the
shell is that the AADV becomes a theranostic agent since the microbubble can be de-
tected using ultrasound imaging techniques while the nanoparticle component delivers
the drug payload. Localized delivery can be monitored using ultrasound to confirm the
nanoparticle is reaching the tumor site.
While in vivo delivery using bound nanoparticles has been shown by other groups,
low frequency piston transducers and focused transducers that do no allow imaging of
the tissue have been used [121; 145]. In this work, using methods developed by Gessner
et al. for molecular imaging, a clinical ultrasound system is used to produce both
ARF and microbubble destruction for delivery [146]. Fluorescent nanoparticles and
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molecules are used in place of drugs while parameters are optimized. It is hypothesized
that enhanced targeted delivery to the tumor will be seen when ARF is applied to the
tumor.
6.2 Materials and Methods
6.2.1 Materials
DSPC, DSPE-PEG2K, and DSPE-PEG2K Biotin were purchased from Avanti Polar
Lipids Inc. (Alabaster, AL). cRGD peptide (Cyclo-Arg-Ala-Asp-D-Tyr-Cys) and cRGD
Biotin-PEG-PEG and were purchased from Peptides International (Louisville, KY).
1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindotricarbocyanine Iodide (DiR) was purchased
from Marker Gene Technologies (Eugene, OR). Blue fluorescent streptavidin coated
nanoparticles were purchased from Spherotech (Lake Forest, IL).
6.2.2 Biotinylated Microbubble Preparation
Lipid solutions were formed using a 9:0.5:0.5 molar ratio of DSPC, DSPE-PEG2K,
DSPE-PEG2K-Biotin in a 90 mL solution of phosphate-buffered saline (Fisher Scien-
tific, Pittsburg, PA). Size isolated microbubbles were created using the method previ-
ously described by Feshitan et al. and Streeter et al. [129; 24]. Briefly, microbubbles
were formed using a sonic dismembrator (Model 500, Fisher Scientific, Hampton, NH)
operated at 70% power for 15 s in the presence of decafluorobutane gas (SynQuest Labs,
Alachua, FL). The microbubble solution that was then centrifuged to isolate desired
populations of microbubbles. Concentrations and size distributions of the microbubbles
were obtained using a laser light obscuration and scattering device (Accusizer 780A,
Particle Sizing Systems, Santa Barbara, CA).
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6.2.3 Targeted Nanoparticle and Microbubble Preparation
Targeted nanoparticles were formulated by mixing cRGD biotin PEG with fluo-
rescent streptavidin coated nanoparticles for 30 minutes on a rotating plate. Coated
nanoparticles were then incubated with biotinylated microbubbles and mixed for an
additional 30 minutes in a 3 mL syringe. The syringe was placed in a 6◦C refriger-
ator overnight in an upright position to allow a layer of AADVs to form at the top
of the solution; unbound nanoparticles remained in the infranant. The top layer was
resuspended in 1 mL PBS. Concentration and size distributions were obtained with an
Accusizer 780A prior to in vivo use.
6.2.4 Targeted Fluorescent Microbubble Preparation
Targeted fluorescently labeled microbubbles were formed similarly to the above bi-
otinylated microbubbles. A 9:0.5:0.5 molar ratio of DSPC, DSPE-PEG2K and DSPE-
PEG2K cross-linked to a cRGD peptide was combined in a 90 mL solution of phosphate-
buffered saline. The 1.5 mL lipid solution was aliquoted into a 3 mL vial with 2 µL DiR
and gas exchanged. Microbubbles were shaken using a VialMix and then transferred
into a 5 mL syringe. The solution was washed by centrifuged three times for 3 min
at 1500xG. The final solution was resuspended in 1 mL PBS. Concentration and size
distributions were obtained using an Accusizer 780A prior to in vivo use.
6.2.5 Animal Preparation
All animal studies were conducted in accordance with protocols approved by the
University of North Carolina School of Medicine’s Institutional Animal Care and Use
Committee. Both rats and mice were used as part of these investigations. Fischer 344
rats (Charles River Laboratories, Durham, NC, USA) were implanted with fibrosarcoma
(FSA) tumor tissue in the right flank. Once tumors reached approximately 1 cm in
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diameter they were used for the study. Balb/c mice were injected with 1x106 4T1 mouse
mammary carcinoma cells. Once tumors reached approximately 0.5 cm in diameter they
were used for this study.
6.2.6 Ultrasound Procedure
A Siemens Accuson Sequoia 512 system (Mountain View, CA, USA) and a 15L8
transducer at 7 MHz were used for this study to image the tumor and deliver the
AADVs with ARF and microbubble destruction. The transducer was positioned using
a three-axis translational motion stage setup (Fig. 6.1). The transducer was swept
in the elevational direction across the tumor by a computer-controlled motion stage
(Model UTS150PP; Newport, Irvine, CA, USA) interfaced through LabView (National
Instruments, Austin, TX, USA) on a desktop computer. ARF pulses were generated
in pulsed wave (PW) Doppler mode at a frequency of 7 MHz. Adjusting the gate
size (18 mm), location of the gate within the field (65 mm), and blood velocity scale
(1 m/sec) created a 25% duty cycle pulse with a PRF of 25 kHz (approximately 70
cycles). Microbubble destruction was achieved in D-color mode with a scan velocity of
5 m/s. ARF pressure was determined in previous work to be 13 kPa [146].
Animals were anesthetized in an induction box at 5% inhaled isoflurane anes-
thesia mixed with oxygen, and maintained at 2.5%. Animals were then placed on a
heating pad to maintain body temperature at 37◦C and prepped for imaging. The area
to be imaged was shaved, further depilated using a chemical hair remover, and then
coupled to the ultrasound transducer using gel. A tail vein catheter was inserted for
microbubble administration. A B-mode scan of the tumor volume was performed to de-
termine proper scan length. Approximately 2x108 microbubbles were injected through
a tail vein catheter, followed by 100 µL saline flush. One minute after injection, ARF
was applied to the tumor as the transducer scanned across at a constant speed of 1
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Figure 6.1: A Siemens Accuson Sequoia 512 system was used to image, apply radiation
force, and destroy loaded microbubbles. A motion stage (right) was used to scan the
transducer across the tumor volume.
mm/s. 5 ARF scans were performed.
After waiting approximately 10 min for freely-circulating bubbles to clear from the
animal’s system, a 3-D imaging scan of the tumor was acquired in Cadence Pulse
Sequence (CPS) contrast imaging mode; the interplane step size was 400 mm. The
bound microbubbles were then destroyed using a high mechanical index B-mode 3-D
scan. The tumor was imaged again in CPS mode at the same slice locations for a
baseline measurement without contrast agents present.
Animals were divided into 3 groups. Group 1 animals served as control without
ultrasound or AADV injection. Group 2 received an injection of AADVs followed
by microbubble destruction 10-12 minutes after injection. Group 3 received AADV
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administration immediately followed by radiation force; microbubble destruction was
performed 10-12 minutes after injection. Subsequent studies without destruction were
performed to evaluate passive and enhanced targeting of the AADVs. Animals were
sacrificed 15 minutes after injection and the tumor tissue was harvested for further
analysis.
6.2.7 Optical Imaging
Harvested tumor tissue was placed in a 6 well plate, and imaged with an IVIS
Kinetic optical imaging system (PerkinElmer; Waltham, MA).
6.3 Results and Discussion
6.3.1 Nanoparticle Loaded Microbubbles
Loading of the nanoparticles onto the microbubbles was confirmed by optical imag-
ing of the resuspended AADV solution. A fluorescent signal was detected from the
microbubbles, however, no signal was seen from the infranant (Fig 6.2). This indi-
cates that the nanoparticles were successfully bound to the microbubbles and could
be isolated from the solution. The AADV solution was then diluted to ensure less
concentrated solutions would also provide signal.
Further optical imaging tests were performed to examine if the signal from the
fluorescent nanoparticles could be detected through tissue. The AADV solution was
placed under harvested tumor tissue and imaged. The particles could be detected
through the tissue (Fig. 6.3).
6.3.2 Radiation Force Targeting
Results from optical imaging revealed no difference in fluorescent signal from tis-
sues with or without radiation force treatment (Fig. 6.4). These results indicated that
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Figure 6.2: After washing, optical imaging of the AADV solution confirmed binding.
Imaging parameters were Ex. 640 nm, Em. 680 nm, EM Gain 50, 2 s exposure. The
top well, which contained the unused washing solution, did not provide a signal.
the concentration of fluorescent particles delivered to the tumor was too low to be de-
tected or the nanoparticles were not remaining targeted to the tissue after microbubble
destruction.
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Figure 6.3: The AADV solution was placed beneath harvested control tumor tissue
to test signal penetration through tissue. Settings: Ex. 640 nm, Em. 680 nm, 1 s
exposure.
62
F
ig
u
re
6.
4:
O
p
ti
ca
l
im
ag
in
g
of
h
ar
ve
st
ed
tu
m
or
s
d
id
n
ot
sh
ow
ev
id
en
ce
of
n
an
op
ar
ti
cl
e
d
el
iv
er
y.
In
cr
ea
si
n
g
th
e
ga
in
se
tt
in
gs
(B
)
d
id
n
ot
am
p
li
fy
n
an
op
ar
ti
cl
e
si
gn
al
;
th
e
co
n
tr
ol
ti
ss
u
e
w
it
h
ou
t
N
P
ex
p
os
u
re
h
ad
th
e
h
ig
h
es
t
si
gn
al
.
Im
ag
in
g
se
tt
in
gs
w
er
e
A
:
E
x
.
64
0,
E
m
.
68
0,
1
s
ex
p
os
u
re
;
an
d
B
:
E
x
.
64
0
n
m
,
E
m
.
68
0
n
m
,
1
s
ex
p
os
u
re
E
M
G
ai
n
50
.
63
To investigate the signal strength of the AADV solution, a biodistribution study
with whole body imaging was performed in a non-tumor bearing female FVB mouse
(Fig. 6.5). The fluorescent signal from the AADV solution was not brighter than the
background signal from the mouse.
Figure 6.5: To investigate the in vivo signal strength of the AADV solution, whole body
imaging after a tail vein injection. Left: FVB mouse after injection; center: control FVB
mouse without AADV injection; right: AADV solution in syringe. Imaging settings
were Ex 640 nm, Em. 680 nm; 1 s exposure.
To further study the effects of the radiation force to enhance delivery in vivo, a
fluorescent (DiR) microbubble was used for subsequent studies in place of the nanopar-
ticle loaded microbubble. A pilot study (N=1 per group) performed in Balb/c mice
with 4TI tumors revealed increased signal from tumor tissue after radiation force was
applied compared to passive targeting (Fig. 6.6).
Subsequent studies, however, did not show increased fluorescent signal. It was
hypothesized that the microbubbles were not targeting. To explore this hypothesis,
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Figure 6.6: Optical imaging of harvested tumors after DiR MB were injected into a
Balb/c mouse. Top left: radiation force was applied followed by microbubble destruc-
tion. Imaging settings were Ex. 745 nm Em. 800 nm, 1 s exposure, EM Gain 50.
DiR labeled cRGD microbubbles were injected into two rats with FSA tumors. Tumor
and liver tissue was harvested after DiR injection with ARF and DiR injection without
ARF. The strong fluorescent signal from the liver, but not tumor illustrates that the
DiR microbubbles are detectable in vivo, but were not successfully targeting to the
tumor.
There are several possible explanations for the limited success seen with ARF en-
hanced delivery of nanoparticles to the tumor tissue. While this method of using a
clinical ultrasound scanner to deliver ARF to enhance targeted microbubble delivery
has been successful for molecular imaging applications, it could be better optimized for
nanoparticle delivery. Due to the wait time between the ARF and the microbubble de-
struction scans, the AADVs and DiR microbubbles were both designed to be targeted
to the endothelium. Unlike in Chapter 4, the break pulse did not come immediately
after the push force and the microbubbles would be carried away by the blood flow
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Figure 6.7: After administration of DiR microbubbles and ARF (top row) or without
ARF, tumor and liver tissue were harvested. Settings: Ex.745 nm, Em. 800 nm, EM
Gain 50, 1 s exposure.
without a targeting component to tether the microbubbles in place. However, target-
ing could be compromised by the stage of tumor development. Expression levels of
αvβ3 and vascular density can change as the tumor grows which could inhibit the ef-
fectiveness of using cyclic RGD labeled nanoparticles and microbubbles. These studies
were also limited by low numbers of animals in each treatment group. Additionally
multiple tumor models were used, making comparisons of delivery methods difficult.
Other researchers have shown enhanced delivery into tumors with significant dif-
ferences in efficacy using drug loaded nanoparticles. Increased delivery seen by others
was a result of destroying the microbubbles immediately after injection [115; 145; 147].
However, in the method utilized with the application of ARF, if the AADVs were not
targeting, the break pulses would not be effective. Future work will examine various
waiting periods to find the optimal timing for ultrasound with and without the addition
of ARF.
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Early experiments were also limited by the inability to detect the nanoparticles.
Attempts were made to extract the particles from digested tumor tissue by centrifu-
gation, but it was not possible due to the small size of the particles. Analysis of the
particles and loaded MB by flow cytometry were also hindered by nanoparticle aggre-
gation. Blue nanoparticles (Ex. 640 nm, Em. 680 nm) were selected so that the signal
could be differentiated from the tissue. However, these particles could not be loaded
onto MB in high enough concentrations to be seen in vivo (Fig. 6.5). Alternative
methods include real time in vivo analysis using an insertable optical imaging device.
Sectioning the tumor tissue after nanoparticle administration and ultrasound exposure
is also an alternative method that could be explored. Several groups have been able
to detect nanoparticles outside of tumor vasculature though tissue histology [115; 145].
Replacing the fluorescent particle with a drug could also help overcome the limitations
of detection using optical imaging.
Work published by Burke et al. has shown that nanoparticles can be delivered both
to the endothelial cells of the tumor vasculature as well into the extracellular matrix
of the tumor [145]. Enhancing cytotoxic drug delivery to endothelial cells may still
provide a way to halt tumor growth. It has been shown that damaging the endothelial
cells within tumor makes tumors more susceptible to chemotherapeutic drugs [148].
The treatment given by Burke et al. was over an hour of ultrasound exposure. Shorter
treatment times would be more practical both for continuing with preclinical studies
and for moving forwards clinical testing.
Future work will continue to optimize settings using a system capable of imaging
the tumor while treating. The ability to image using ultrasound and microbubbles
contrast agents allows for confirmation that the tumor is vascularized. This is an
important characteristic to determine since the delivery can only be achieved if the
agents can circulate through the targeted area [149].
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6.4 Conclusions
Variations of an AADV using targeted fluorescent nanoparticles were used in com-
bination with a clinical ultrasound system to target the nanoparticles to tumor tissue.
Enhancement of fluorescent lipid within the tumor was seen using a DiR microbubble
and acoustic radiation force, however a limited number of animals was used. Future
work will use other methods to evaluate delivery to avoid problems with weak signal
from fluorescent nanoparticles.
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CHAPTER 7
Pharmacokinetic Analysis of Ultrasound Mediated PEGylated Liposomal
Doxorubicin Delivery to Tumors
7.1 Introduction
While several studies have shown ultrasound enhanced delivery of nanoparticles (see
Appendix A), there is limited work that investigates these effects from a pharmacolog-
ical perspective. How a drug is distributed through the body and its mechanism of
action are core components to drug delivery. These parameters are evaluated through
pharmacokinetic (PK) and pharmacodynamic (PD) studies. PK examines the time
course of the drug concentration in the body, or what the body does to the drug.
Drug absorption, distribution, metabolism, and excretion are the primary areas that
are studied. PD examines the effect and mechanism of action of the drug, or what
the drug is doing to the body. By design, nanoparticles have very different pharmaco-
logic profiles when compared to their small molecule counterparts. Longer circulation
times, slower release kinetics, and altered uptake throughout the body are often seen
with nanoparticles. One of the large unanswered questions in the field of ultrasound
mediated nanoparticle drug delivery is what happens to the nanoparticles and bubbles
after administration. During a co-administration of microbubbles and nanoparticle
Unpublished work by LB Mullin, LC Phillips, G Song, WC Zamboni and PA Dayton
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drugs, it is hypothesized that the application of ultrasound at the target (tumor) site
while microbubbles are circulating will enhance uptake of the nanoparticle due to de-
sirable bioeffects that result from exposing the microbubble to sound waves, causing
oscillation and destruction, which leads to enhanced cellular and vascular permeabil-
ity. This increased permeability will allow a larger amount of drug/nanoparticles to
enter into the tumor tissues, hopefully resulting in a more effective cancer treatment.
While multiple groups have shown reduced tumor growth with ultrasound treatment,
information about what is happening at the site of ultrasound application is relatively
limited. Here we use novel methods to detect both encapsulated and released doxoru-
bicin levels within plasma and total doxorubicin concentrations within tumor tissues of
mice treated with PEGylated liposomal doxorubicin (PLD), microbubbles and focused
ultrasound.
7.2 Materials and Methods
7.2.1 Microbubble Preparation
A lipid mixture 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-distearoyl-
sn-glycero-3 phosphoethanolamine-N-[methoxy- (polyethylene glycol)-2000] (ammonium
salt; DSPE- PEG2K; Avanti Polar Lipids) was prepared using a 9:1 molar ratio. Briefly,
lipids were dissolved in chloroform, dried and dissolved into a buffer solution of PBS.
The lipid solution was then transferred into vials, which were then evacuated and filled
with decafluorobutane gas. Vials were shaken with a Vialmix shaker (Bristol-Myers
Squibb Medical Imaging, North Billerica, MA) for 45 s prior to injection. Microbub-
bles had a mean diameter of 0.71 µm and a concentration of 1.0x1010 MB/mL.
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7.2.2 PLD Preparation
PEGylated liposomal doxorubicin (PLD) at was diluted in 5% Dextrose Injection,
USP (D5W) prior to use. The dose used in all animals was 6 mg/kg.
7.2.3 Animal Preparation
Animals were handled according to National Institute of Health guidelines and the
study protocol was approved by the UNC Institutional Animal Care and Use Commit-
tee.
Study 1
Studies were performed with a C3Tag genetically engineered mouse model (GEMM)
that spontaneously develops mammary carcinoma tumors. When tumors reached ap-
proximately 7 mm, treatment was given.
Mice were anesthetized at 2% isoflurane on a heating pad and maintained at 1-
2%. A 27 gauge catheter was inserted into the tail vein for administration of PLD
and microbubbles. The transducer was placed above the center of the tumor with gel
between the tumor and transducer.
Mice were treated with a Philips Therapy Imaging Probe System operated at 1 MHz,
1 MPa, 10% duty cycle, and 10 Hz pulse repetition frequency (Fig. 7.1). The transducer
was programmed to scan the tumor volume, 5 s at each location. Microbubbles were
diluted 1:1 in saline; 100 µL microbubbles were slowly injected by hand while ultrasound
was applied to the tumor. PLD at 6 mg/kg was injected via the catheter following
microbubble and ultrasound treatment.
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Study 2
Studies were performed in FVB mice injected with cells derived from an autochthonous
(GEMM), the C3Tag (5x105 cells/injection). Tumors were treated once they reached
approximately 5-7 mm in diameter.
Mice were anesthetized at 2% isoflurane on a heating pad and maintained at 1%.
A catheter was inserted into the tail vein. The transducer was placed above the center
of the tumor with gel between the tumor and transducer.
Mice were treated with a Philips TIPS operated at 1 MHz, 1 MPa, 50% duty cycle,
10 Hz pulse repetition frequency (Fig. 7.1). The transducer was programmed to scan
the tumor volume, 5 sec at each location. PLD at 6 mg/kg was injected prior to
MB/US treatment. Microbubbles were diluted 1:9 in saline; 100 µL of microbubbles
were injected slowly by hand during the duration of the ultrasound treatment.
Control mice were treated with an injection on 6 mg/mL PLD.
7.2.4 Pharmacokinetic Study Design
Mice were sacrificed at 0.083, 1, 6, 24, 48 and 96 h (Study 1) and 1, 6, and 24 h
(Study 2) after administration of PLD. Approximately 1 mL of blood was collected via
terminal cardiac puncture following deep anesthesia and placed on ice in polypropylene
screw cap tubes. Tumor tissue was divided into sections for PK analysis, IHC, and
fluorescence imaging. Tumor and other tissues (lungs, liver, spleen, kidney) were placed
in cryopreservation vials and preserved by snap freezing in liquid nitrogen. All tissue
samples were stored at -80◦C until processed.
7.2.5 Sample Processing and Analytical Methods
After collection, blood samples were immediately centrifuged at 1,500xG for 5 min-
utes to collect plasma. Samples were not frozen in order to avoid rupturing the liposome
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structure. Solid phase separation (SPS) was carried out for the determination of en-
capsulated and released doxorubicin. SPS columns were preconditioned with PBS and
methanol. An internal standard solution of daunarubicin in PBS was added to each
column after the addition of each spiked sample. The encapsulated fraction was col-
lected and stored at -80◦C. The released doxorubicin was eluted from the column with
methanol and evaporated in a TurboVap (Caliper Lifesciences, Hopkinton, MA) under
nitrogen flow at 45◦C. Samples were reconstituted in 150 µL of 85:15 Acetonitrile: wa-
ter with 0.1% formic acid, and vortexed for 10 minutes. 125 µL were transferred to a
200 µL plastic inset in a HPLC autosampler vial. Vials were centrifuged for 10 min at
3,000xG. Samples were analyzed by HPLC using fluorescence (FL) detection with an
excitation wavelength of 490 nm and emission wavelength of 590 nm.
The encapsulated fraction was further processed to determine concentration of dox-
orubicin within the carrier using protein precipitation with acetonitrile. Samples were
removed from the freezer and allowed to reach room temperature. 2 mL of acetonitrile
with Daunorubicin was added to all samples and vortexed for 10 minutes. Samples
were then centrifuged for 5 minutes at 1,000xG before transferring 1 mL of the organic
phase to a 5 mL propylene tube. The organic phase was then evaporated in a Turbo-
Vap. Samples were reconstituted with 150 µL mobile phase and mixed by vortex and
centrifugation before being transferred to autosampler inserts. Samples were analyzed
by HPLC in the same methods as the released doxorubicin.
To form tumor homogenates, tumors were thawed and sectioned. The sections were
weighed and diluted in a 1:3 ratio with DI water. These mixtures were homogenized by
placing zirconium oxide beads (15 small and 2 large; Omni International Inc, Kennesaw,
GA) into 2 mL tubes at 3,000xG using a Precellys 24 homogenizer (Omni International
Inc, Kennesaw, GA) twice for 40 s each with a 20 s wait between each run.
An extraction solution composed of daunorubicin and acetonitrile was placed into
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a microcentrfigue tube filled with tumor homogenate, vortexed, and centrifuged at
10000xG for 10 minutes at 4◦C. 850 µL of the supernatant was transferred to a 2 mL
tube and evaporated under nitrogen in TurboVap and reconstituted in 150 µL of the
mobile phase.
After vortexing for 10 min, 125 µL of reconstituted samples was transferred to a
200 µL plastic inset in a HPLC autosampler vial. Vials were centrifuged for 10 min at
3000xG before being analyzed by HPLC using fluorescence detection with an excitation
wavelength of 490 nm and emission wavelength of 590 nm using an injection volume of
10 µL.
7.2.6 Pharmacokinetic Analysis
Pharmacokinetic parameters for encapsulated, released, and sum total doxorubicin
were calculated by non-compartmental methods using Phoenix WinNonlin (Pharsight
Corp., Mountain View, CA). The area under the concentration versus time curve from
0 to 24 h (Study 2) or 96 h (Study 1) was calculated using the linear up/log down
rule. The plasma volume of distribution (Vd), clearance (CL), and half-life (t1/2) were
calculated using standard equations. The maximum concentration (Cmax and time of
Cmax (Tmax)) were determined by visual inspection of the concentration versus time
data.
7.3 Results
7.3.1 Study 1
Pharmacokinetic parameters from ultrasound treated mice were compared to previ-
ous data collected previously in C3Tag mice receiving only 6 mg/kg PLD [150]. AUC
values revealed elevated amounts of doxorubicin within the tumor, along with an in-
crease in encapsulated and released plasma level (Table 7.2).
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Table 7.1: Study 1PK Parameters C3Tag GEMM
Parameter Units Plasma Plasma Tumor
Encapsulated Released
MB, US, PLD
HL hr 26 61
Tmax hr 1 1 96
Cmax ng/mL 86369 1181 16627
SE Cmax ng/mL 11973 103 4141
Tlast hr 96 96 96
Clast ng/mL 5395 212 16627
AUClast hr*ng/mL 2976370 68126 1176218
SE AUClast hr*ng/mL 419407 9629 166937
Vd mL/kg 72
CL mL/hr/kg 1.9
PLD
HL hr 15.10 16.92 40
Tmax hr 0.08 0.50 24
Cmax ng/mL 82,760 1,712 6534
SE Cmax ng/mL 17,200 277 1895
Tlast hr 96 96 96
Clast ng/mL 1,199 19 2388
AUClast hr*ng/mL 1,609,775 30,818 480111
SE AUClast hr*ng/mL 111,180 2,840 71419
Vd mL/kg 79.91
CL mL/hr/kg 3.67
Visual inspection of the concentration over time curves reveals differences between
PLD control and PLD ultrasound treated concentrations (Fig. 7.2). Plasma doxoru-
bicin levels decreased then increased at 48 h post treatment. Sum total values within
the tumor decreased at 6 h post treatment, but increased after 24 h.
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Table 7.2: GEMM C3Tag AUC Values
AUC Plasma AUC Plasma AUC Tumor
Encapsulated Released
Ultrasound 2,976,3709 68,126 1,176,218
No Ultrasound 1,609,775 30,818 480,111
Percent Difference 60 75 84
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Ratios of tumor to plasma levels were also calculated (Table 7.3).
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Figure 7.3: Nine of the C3Tag mice in Study 1 had secondary tumors not exposed
to tumors. Doxorubicin values within the insonated and non insonated tumors are
compared in the plot.
Multiple mice within the ultrasound microbubble treatment group also had sec-
ondary tumors which were not treated with ultrasound. These tumors were harvested
and the doxorubicin concentration was compared to the treated tumor (Fig. 7.3). Both
of the mice sacrificed 96 h after treatment had increased doxorubicin with ultrasound
exposure. This aligns with the Tmax of 96 h seen in Study 1 mice treated with ul-
trasound and microbubbles. At 48 h the largest difference between tumors was seen,
however the increase in 2 out of the 3 mice was in the tumor without ultrasound.
7.3.2 Study 2
The concentration time curves of doxorubicin within plasma and tumor tissue is
displayed in Figure 7.4. The profiles of the concentrations within mice that received
only PLD and the mice that received PLD with microbubbles and ultrasound are very
similar.
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Table 7.5: Study 2:PK Parameters Implanted C3Tag Mice
Parameter Units Plasma Plasma Tumor
Encapsulated Released
MB, US, PLD
HL hr 21
Tmax hr 1 1 24
Cmax ng/mL 110712 968 13960
SE Cmax ng/mL 18363 127 1520
Tlast hr 24 24 24
Clast ng/mL 50377 439 13960
AUClast hr*ng/mL 1819984 17380 247921
SE AUClast hr*ng/mL 167904 1000 14750
Vd mL/kg 54.5
CL mL/hr/kg 1.8
PLD
HL hr 27
Tmax hr 1 1 24
Cmax ng/mL 98052 1225 10791
SE Cmax ng/mL 6827 195 2109
Tlast hr 24 24 24
Clast ng/mL 51757 820 10791
AUClast hr*ng/mL 1638623 20685 191470
SE AUClast hr*ng/mL 41355 1644 30180
Vd mL/kg 64.4
CL mL/hr/kg 1.6
Ratios of tumor to plasma levels were also calculated (Table 7.4).
7.4 Discussion
In the field of preclinical drug delivery, there is debate over the appropriate mouse
model to use for studying drug formulations. There are several options of tumor mod-
els, which include syngeneic and xenograft mouse tumors or autochronous models such
as genetically engineered mouse models that have genetic mutations that cause sponta-
neous tumor development. Syngeneic models are mouse tumors injected or implanted
ectopically or orthotopically (within the organ of origin). These are advantageous
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Table 7.6: Implanted C3Tag AUC Values
AUC Plasma AUC Plasma AUC Tumor
Encapsulated Released
Ultrasound 1819984 17379 247921
No Ultrasound 1638623 20685 191470
Percent Difference 10.5 -17.3 25.7
because they do not require immunocompromised mice, are low cost and are highly re-
producible [151]. However, they may not accurately represent the human condition of
this disease [152]. Xenograft models use human cells/tumors in a murine environment.
This model is also cost effective and reproducible, but interactions between cells from
different species may produce tumor environments that are not an accurate model of
the human tumor microenvironment. These transplantable models may also lead to
misrepresentations of the tumor environment with respect to vessel permeability. A
possible solution to these problems is the use of GEM models that develop tumors in
the appropriate organ, but these studies can be difficult to use due to the delayed onset
of tumor and low tumor incidence within mouse colonies [151].
Both because of the difficulty in acquiring appropriate animals per treatment group,
and the differences in tumor environment, two types of models were used for this
investigation into the pharmacokinetics of PLD combined with ultrasound treatment.
Study 1 used a GEM model, whereas Study 2 was conducted in a orthotopic syngenic
model.
In Study 1, PLD alone treatments were performed previously by collaborators [150].
Ultrasound parameters were selected based on a review of the literature. Similar studies
performed by Lin et al. saw increased delivery at 24 h post treatment with a similar
setup, and this was selected as an end time point for preliminary studies [115].
Tumors developed from cell injections, may have increased permeability compared
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to GEMMs. Changing the tumor model for Study 2 allowed investigation into if this
concept could be seen for C3Tag tumors. Additionally, the implanted tumors have a
more predictable tumor growth pattern which aids in study feasibility.
Ultrasound parameters that were modified between studies include increased duty
cycle from 10% up to 50%. Increasing the duty cycle increased overall ultrasound
exposure within the tumor. The microbubble were also diluted 1:9 instead of 1:1.
As discussed in Chapter 3, microbubble concentration can play an important role in
increasing permeability.
In both studies, elevated concentrations of doxorubicin were found in the tumor with
the application of ultrasound. However, along with elevated tumor levels, plasma levels
were also elevated in the animals treated with ultrasound. This data could indicate
the microbubbles circulating with the liposomal doxorubicin may interfere with MPS
clearance of the drug. Further investigation into how the circulating nanoparticles are
recognized by the immune system could provide more details on this mechanism. Alter-
natively, it is possible that in the current method of delivery, there is not a significant
increase in drug concentration within the tumor, but that other mechanisms might be
responsible. This could be supported by data shown in Figure 7.3. An efficacy study
performed over 6 weeks with a weekly treatment schedule will investigate the efficacy
of the ultrasound treatment to inhibit tumor growth.
Additional time points for Study 2 could support the trend of a increase at 24 hours
post treatment in the ultrasound group compared to PLD control. In Study 1, the
concentration time curves become more distinct after 25 h, however this data has not
be obtained yet for Study 2.
While it was hypothesized that ultrasound in the presence of microbubbles would
increased the drug concentration at the tumor site, it is possible other mechanisms may
have a more important role when the drug is not bound to the microbubble. Analysis of
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the untreated secondary tumors in Study 1 may indicate that the ultrasound parameters
may need to be adjusted in hopes of increasing the drug concentration within the
ultrasound treated tumor. The data presented in Figure 7.3 is not normalized to tumor
volume. When multiple tumors were present in an animal, the tumor most accessible
by ultrasound (away from the head) was selected. Most times this was also the larger
of the two tumors.
Previous studies have shown that the order of administration does not effect nanopar-
ticle uptake within the tumor [98], yet the state of nanoparticles, liposomes in partic-
ular, has been under investigation. It is possible that variations in the ultrasound
settings may provide an environment where liposomes would rupture. This would be
an additional methods of causing a spike in drug concentrations within tumor tissue.
However, data presented here also indicate that the ultrasound is not breaking the
liposomes. In Study 2, PLD was administered prior to ultrasound exposure, yet there
was not an increase in released doxorubicin concentration (Table 7.4). Although Study
1 does show an increase compared to without ultrasound, the PLD was administered
after the tumor was exposed to ultrasound and is therefore not responsible for the
difference.
Future studies with bound nanoparticles will allow a greater understanding of the
impact of route of administration- whether the drug is administered separated, or joined
to the microbubble. Nanoparticles are known for their long circulation times, however
binding the agent to the microbubble may cause the drug to decrease from hours or
days of circulation, down to minutes. While the full clinical implications of this change
in pharmacokinetic profile are unknown, it is believed that delivering a higher amount
of drug to the tumor, but limiting systemic exposure may achieve a greater therapeutic
index.
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7.5 Conclusions
The effects of ultrasound and microbubbles on doxorubicin pharmacokinetics were
investigated. Two animal models and two sets of ultrasound parameters were studied.
Elevated doxorubicin levels were seen both in the plasma and the tumor for Study
1 when ultrasound was applied. Encapsulated drug levels and total drug within the
tumor were elevated in Study 2 with the addition of ultrasound. Future work involving
efficacy studies and longer time points will provide more information about possible
mechanisms causing the increased tumor uptake.
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CHAPTER 8
Concluding Remarks
8.1 Summary
The work presented in this dissertation works towards the application of ultrasound
and microbubbles to enhance nanoparticle drug delivery. Studies advance from in
vitro testing of acoustic and microbubble parameters (Chapters 3 and 4) to in vivo
evaluation of delivery of nanoparticles and therapeutic efficacy (Chapters 5, 6, 7).
Both co-administration and loaded microbubbles are used throughout this work.
Novel contributions include an in depth look at the role of microbubble size in sono-
poration (Chapter 3), where size isolated microbubbles are used. The ability to create
microbubble populations of a specific size range can have many advantages. According
to our data, fewer microbubbles may be need to achieve the desired bioeffects which
increase permeability. In addition, controlled size can allow for controlled loading onto
microbubbles. Knowing the size of the microbubble can allow for tailed ultrasound pa-
rameters to be used, since the resonance frequency of microbubbles is dependent on the
size of the bubble. Acoustic responses, such as oscillation and translation from radia-
tion force, vary based on size. Future work optimizing these settings is still needed, but
c©2013 IEEE. Portions reprinted, with permission, from LB Mullin, LC Phillips, PA Dayton.
“Nanoparticle delivery enhancement with acoustically activated microbubbles” IEEE Trans Ultrason
Ferroelectr Freq Control, 2013; 60(1): 65-77.
88
these results will be important moving forward with ultrasound microbubble enhanced
delivery.
In Chapter 4 a novel nanocapsule loaded microbubble is created. These nanocap-
sules have been shown to overcome drug resistance in tumors [141]. We show the
nanocapsules can be easily modified to bind to the shell of the microbubble. This
loading potential of the microbubble is an appealing characteristic due to the limited
payload that could be retained within the shell itself. In this chapter the ability to
achieve targeted delivery in vitro to a cell monolayer is demonstrated.
In Chapter 5, in vivo co-administration study was performed. Using a therapeutic
ultrasound system, low dose nanocapsules were administered 3 times per week for 2
weeks in combination with microbubbles and ultrasound. The mice receiving nanocap-
sules, ultrasound, and microbubbles had statistically significant tumor volumes on sev-
eral days throughout the study. The use of an aggressively growing tumor was not ideal
for testing the effect of ultrasound mediated delivery as the tumors didn’t respond to
treatment as well as expected. This study only relied on tumor volume to evaluate
drug delivery, and did not measure actual concentration of paclitaxel within the tumor.
Additional limitations of this study are that the control group used for comparing tu-
mor response was from an earlier study, making comparisons difficult, and the dose
selection may have been too low.
In Chapter 7, drug concentrations within plasma and tumor were measured to eval-
uate the effects of ultrasound. The study combined the use of a preclinical commercial
therapeutic transducer with microbubbles and liposome treatment and provides a novel
look at drug concentrations after ultrasound treatment. Analysis methods provided in-
formation about encapsulated and released doxorubicin concentrations up to 96 h after
treatment. Increased concentrations were seen within the tumor tissue, along with
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elevated plasma levels. Future efficacy studies are needed to determine if other mech-
anisms, such as microbubble shielding of the liposomes causes increased levels.
In Chapter 6, a clinical ultrasound system is used to deliver radiation force and
microbubble destruction in vivo. Targeted fluorescent AADVs and targeted fluorescent
microbubbles are injected into tumor bearing rats and mice. Optical imaging methods
were used to assess delivery to tumor tissue. Fluorescent bubble delivery was seen in
preliminary studies. Future work will increase the number of animals treated. Incor-
porating a drug loaded nanoparticle will eliminate issues with tissue autofluorescence
issues and allow for a more precise measurement of the effectiveness of treatment with
a clinical system.
8.1.1 MB Formulations
Throughout this work, various microbubble formulations were used to study the
ability of microbubbles and ultrasound to enhance delivery. Table 8.1 provides details
of each of types of bubbles used, including specific shell components, modifications for
conjugation, size and method used for forming bubbles from the lipid solution. An
advantage to making our microbubbles in our own laboratory is the ability to tailor the
formulation based on the application.
8.1.2 Ultrasound Sources
Several ultrasound systems are also used throughout this work to achieve delivery
(See Table 8.2). In vitro studies were carried out with a piston transducer energized
by a waveform generator and RF amplifier. This system allowed maximum control
of ultrasound settings including number of cycles, PRF, duty cycle and pressure. A
system like this is ideal for investigating the effects of various parameters is a simplified
manner. For example, increasing the pressure for sonoporation studies can be achieved
simply by increasing the voltage signal. These studies demonstrated the ability of
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unfocused and focused ultrasound to manipulate microbubbles. These studies however
did not incorporate imaging uses of ultrasound.
In vivo studies were performed using three different types of ultrasound systems.
The first system used was a commercially available system used for physical therapy
applications. The Sonicator 740 is lightweight, portable system allows for limited con-
trol of frequency, intensity, and duty cycle. The system allowed for parameters to be
easily matched to literature intensity and duty cycle, although full control over the sig-
nal not possible. Duty cycle options are 10%, 20% or 50%, with a set PRF of 100 Hz.
Intensity values up to 2.2 W/cm2 are possible. This transducer was unfocused allowing
for treatment of the entire tumor at once, but did require slight movement of the trans-
ducer to avoid tissue heating due to hot spots on the transducer. Co-administration
of nanocapsules and microbubbles did not require radiation force for delivery, which
made the 1 MHz transducer ideal for treatment. This system again did not allow for
imaging of the tissues.
In Chapter 6, in vivo studies were carried out with a clinical ultrasound scanner.
Settings on the Siemens Sequoia 512 were manipulated to achieve radiation force and
microbubble destruction. This system also allowed for image guidance to be used. CPS
mode was used to image the contrast, which confirmed the loaded vehicle had reached
the tumor site. In order to treat the entire tumor, a motion stage was required to
translate the transducer across the tumor. Multiple types of nanoparticles and targeted
nanoparticles were administered in these studies. Fluorescence detection proved to be
a challenge in these studies.
The final system that was used in this work was the Philips therapy and imaging
probe system (TIPS). This system has been discontinued by Philips. With the TIPS,
a controller PC allows custom programming of the transducer output and scanning
pattern of the transducer over the region of interest. This system is specifically designed
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for use with mice and rats, and it is designed to allow users to treat target areas with
specific ultrasound parameters. This technology is an ideal match for in vivo studies
using the microbubble delivery vehicles developed in the current project. Although it
was not used as part of our study, ultrasound imaging can also be performed with the
system through integration of a higher frequency transducer into the therapy probe.
This will allow precise location of a tumor regions within a subject and exposure of
only the tumor region to ultrasound.
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Table 8.2: Summary of ultrasound systems and settings used for each study in this
dissertation.
Chapter Ultrasound Settings
hline 3 unfocused 1 MHz piston 1 Mhz, 100-1.2 Mpa, 0.15-150 Hz PRF, 5 cycle
3 unfocused 1 MHz piston 1 Mhz, 300 kPa, 150 Hz PRF, 5 cycle
4 focused 2.25 MHz 3.5 MHz, 50kPa; 1.5 MHz, 1.2 MPa
combined 3 s PRF of 150 mHz PRF, 30% DC
5 Sonicator 740 1 MHz 1 MHz, 2 W/cm2, 10% DC
6 Siemens Sequoia 15L8 PW Doppler 7 MHz, 13 kPa, 25% DC,
25 kHz PRF 70 cycles; D Color MI 1.9
7 Philips TIPS 1 MHz, 1 MPa, 10 Hz PRF, 10-50% DC
8.2 Future Directions
The next step in evaluating the use of ultrasound to enhance chemotherapeutic
delivery is to attach a drug loaded nanoparticle to the microbubble to create an acous-
tically active delivery vehicle that can be controlled externally by ultrasound. Attach-
ing a drug containing nanoparticle, may overcome the detection challenges that were
faced in the work described in Chapter 6. Continuing with methods used throughout
this dissertation, future studies that attach doxorubicin liposomes to the microbubble
shell could help increase delivery to tumors. Potential ways to attach the doxorubicin
liposome to the bubbles include using avidinbiotin, maleimide-thiol or carboxylic acid-
amine [153; 154]. Additionally, future work could employ a custom designed TIPS
transducer that operates at both 1 MHz and 3 MHz to achieve both radiation force
and destruction. Using the TIPS in combination with a imaging transducer will ensure
the tumor is being targeted. Harvesting of the tumor and organs would be carried out
and analyzed as done previously in Chapter 7. Special attention would be given to com-
paring concentrations seen in organs such as the liver and spleen when the liposome is
free or bound. It is hypothesized that a greater difference in doxorubicin concentration
will be seen within the tumor compared to free PLD and microbubble administration
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and less doxorubicin will be measured in the plasma.
Future work evaluating drug deposition into tumors can be studied using micro-
dialysis methods could answer questions about how effective ultrasound delivery meth-
ods are at overcoming barriers to delivery such as being able to exit the vasculature
[155; 156]. Using a small probe inserted into the tumor, drug concentrations within the
tumor can be measured over time. These methods can be used to detect both free and
encapsulated doxorubicin within the tumor. This study would provide insight into the
state of the liposome after ultrasound exposure and provide knowledge about whether
the drug is entering into the extracelluar matrix of the tumor. An alternative method
to measure delivery into the tumor would involve using an optical probe that can de-
tect fluorescent signal from a nanoparticle. This could be done using Doxil, which is
fluorescent, or another fluorescent nanoparticle such as the polystyrene beads used in
previous studies. This method may overcome the limitation of previous studies with
weak signal and interference from tissue autofluorescence.
A drug loaded AADV could also be used in future studies performed with the
Sequoia 512 system. As with the TIPS studies, PK analysis of tissues would valuable
information regarding the enhancement effect seen with ultrasound. Future studies
could also take advantage of research software to measure perfusion before and after
treatment. This novel volumetric imaging technique allows quantitative assessment
of blood flow in an entire sample volume, unlike traditional 2-D ultrasound, which
only provides qualitative information in a single slice of tissue [157]. Additionally, the
therapeutic response can be observed in tumors much more accurately by monitoring
blood perfusion versus caliper measurements only.
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8.3 Clinical Translation
There are still many obstacles to overcome to translate microbubble-mediated ul-
trasound delivery of nanoparticles into a clinical setting, but progress is being made
as more in vitro and in vivo studies are being published. Work remains to be done
on understanding the mechanisms taking place in vivo to ensure that safe delivery can
be achieved. Bioeffects will need to be closely monitored, because tissue damage has
been seen in some studies [87]. It will also be important to understand the biodistri-
bution and pharmacokinetics of the nanoparticles when delivered with microbubbles.
As discussed earlier in liposome nanoparticles generally have long circulation times,
but when bound to microbubbles, the complex is limited to the 5 to 10 min circulation
time of the microbubble [57]. Although the microbubble-mediated delivery method will
increase the nanoparticle concentration at the target site, accumulation in other organs
is always a major factor to consider, because drug or gene accumulation in non-targeted
organs/tissues could be detrimental.
Another area that is actively under investigation is the effect of ultrasound on the
integrity of the nanoparticle, and how bound nanoparticles disassociate from microbub-
bles. There have been conflicting reports about how and if the nanoparticle is released
from the shell. Lum et al. detected lipid labeled with DiI on the nanoparticles after
breaking the microbubble [95]. However, other groups have found that the nanopar-
ticle breaks free[54; 60; 113]. Ultrasound exposure has also been shown in some cases
to cause release of the contents [57; 114], whereas in other studies, the cargo remains
intact within the liposome carriers [112; 113].
Loading optimization also needs to be addressed. Liposome loading on microbubbles
has been estimated at between 600 and 10000 liposomes per microbubble, depending on
the size of both the microbubble and the liposome [54; 56; 57]. This may be complicated
further by the fact that lipids are not uniformly distributed through the shell layer of
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microbubble, resulting in heterogeneous loading of nanoparticles [95; 158]. Uniform
loading is desirable to accurately quantify the amount of drug or gene on each bubble,
and therefore delivered to the target site. Optimization of loading is challenging because
it is frequently difficult to determine concentrations of nanoparticle solutions because
of their small size. Although binding can be confirmed through methods such as flow
cytometry, UV spectrometry, and microscopy, exact numbers of bound nanoparticles
are difficult to obtain.
Further optimization of both ultrasound settings and delivery vehicle design are also
needed. Because a variety of systems exist which deliver ultrasound energy, there is
also a wide range of settings in use. Currently, comparisons between studies are hard
to make because of the highly variable acoustic parameters used from study to study.
In addition to ultrasound systems and settings, different microbubble formulations and
nanoparticles are used that influence the results of each study. Further refining of
microbubble populations through size selection techniques may be a way to improve
the effectiveness of delivery methods. Microbubble populations with high uniformity
in size may allow optimal loading of particles onto the shell and better prediction of
the microbubble’s response to ultrasound [159; 160]. Additionally, further study of the
tradeoffs between bound and free nanoparticle delivery is needed for each application.
Translating research into the clinic is a very slow process. Drug development can
easily take beyond 10 years. Ultrasound enhanced nanoparticle drug delivery has more
than one component that will need to be approved/cleared by the FDA. However,
this can be managed by working with already available drug formulations, contrast
agents, and ultrasound systems. Although not with optimized parameters, the concept
can be, as has already been, demonstrated in a clinical system. Recently one of the
first clinical studies investigating the use of microbubbles and ultrasound to enhance
efficacy of chemotherapeutic treatment has been published [161]. Five patients with
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nonresectable pancreatic adenocarcinoma were treated using A GE LOGIQ 9 scanner,
4C transducer, SonoVue microbubbles and gemcitabine chemotherapy. A comparison
to a control group of 80 patients treated with gemcitabine alone showed that ultrasound
treatment increased the number of treatment cycles, prolonging the quality of life in
patients with pancreatic adenocarcinoma. This first of its kind study provides hope
that ultrasound exposure will contribute to improving cancer care in patients.
Safety is a major concern for bringing any new drug or device to market. While
both ultrasound imaging and microbubble contrast agents are generally regarded as
safe, there have been concerns in the past regarding safety of the microbubbles. After
four deaths were reported in patients who had been administered contrast, the FDA
issued a black box warning in 2007 which listed several contraindications and monitoring
requirements [162]. After a review of the data, the warning was modified to only include
contraindications for patients with known hypersensitivity to perflutren, (or albumin
for Optison), patients with fixed cardiac shunts. These changes to the label affected the
use on contrast in clinics, and may still hinder advances in contrast imaging/therapy
in the United States [163].
Introducing microbubble agents for use in therapy, where bioeffects are desired,
presents more safety issues that will need to be addressed. Extensive research will
need to be done to demonstrate the effects are restricted to the desired location, and
not negatively impacting surrounding tissues. These studies can be done by monitoring
surrounding areas for changes in temperature, blood flow, or other tissue characteristics
[164].
FDA limits on output exist for diagnostic imaging in order to prevent thermal effects
and cavitation. These limits are on the mechanic index (MI)- must be below 1.9 and
the spatial peak time averaged intensity (Ispta) must be below 720 mW/cm
2. These
limits were established in 1976, and do not necessarily accurately represent the limits
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of safe use of ultrasound. Additionally, these settings are for diagnostics, and therefore
the development of a therapy system does not necessarily have to operate within these
limits. Currently there are numerous therapeutic ultrasound systems that have been
cleared by the FDA which fall outside of these limits. In HIFU, intensities of up to
10,000 W/cm2 are use to treat tumors and uterine fibroids. Lower intensity systems are
in use in physical therapy clinics for heating tissues and treating bursitis and tendinitis.
The existence of these systems may improve the likelihood for approval of a system for
drug delivery.
Beyond the hurdles of FDA clearance/ approval, there are limitations to the method
of treating tumors with ultrasound and microbubbles. The tumor needs to be accessible
to interrogation from the ultrasound beam, which puts limits on types of tumors and
sites. For example, tissues deep within in the body or within the lungs would be difficult
due to signal attention and air reflections, respectively. This also requires the location
of the tumor to be known. Many cancers metastasize, and small molecule drugs will be
able to attack these cells with more success than spatially localized tumor. Combining
ultrasound-mediated treatment with other treatment options may be a solution to this
drawback.
Creating one system that fits all the ideal characteristics may not be realistic, espe-
cially when drug loaded microbubbles are in use. Treatments with various drugs would
require a new AADV. A single bubble, however, could be designed to be used when
co-administration is the route of delivery.
In an ideal system, the location to be treated would be visualized using ultrasound
imaging, the region to be treated would be selected, such as with an ROI tool, and
the therapeutic ultrasound would be applied only to this region. This requires that
information. Control over frequency, pulse length, duty cycle, pressure, is needed and
99
should also be displayed. In order to avoid damage to tissues above or below the treat-
ment area, focused treatment should be used. This also would require the transducer
to be moved across the area. Detailed information about the ultrasound pulse, such as
axial, lateral, and elevational full-width half-max of the ultrasound pulse, is needed to
determine the necessary adjustments to treat the desired area. How the microbubble
and drug are linked, or not linked, will impact the type of ultrasound system that will
be needed. For co-administration, imaging and destruction pulses are needed; using
bound AADVS would require the addition of radiation force pulses. ARF pulses are
typically longer than that is used in diagnostic imaging, however, and modifications
to current clinical scanners can be use to alter settings such as pulse length that are
needed for optimized radiation force.
Other types of systems to consider for ultrasound drug delivery are intravascular
ultrasound systems that would release the microbubbles and drug internally form the
same location the ultrasound is emitted. The feasibility and effectiveness of this type
of treatment has been shown by multiple groups [165; 117].
8.4 Conclusions
Microbubbles are an appealing choice for enhancing nanoparticle targeted drug de-
livery. Nanoparticle chemotherapeutics can be combined with the microbubbles, and
through the external control of ultrasound, localized delivery can be achieved. There
are still many areas that require further investigation, however, many advances are
being made in the use of ultrasound and microbubbles and the approach is developing
into a promising method to improve cancer treatments.
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APPENDIX A
Review of Nanoparticle Delivery Studies
Table A.1: Summary of In Vitro Studies. Abbreviations used in the table: cycle (C),
cycles per pulse (CPP), duty cycle (DC), pulse repetition frequency (PRF), peak to
peak (p-p), quantum dots (QD), frame rate (FR), pulse length (PL), pulse repetition
period (PRP), polystyrene (PS), biotin-avidin (B-A), and maleimide-thiol (M-T).
Ref. Transducer Settings MB NP Linked? Model
[166] Unfocused 1 MHz, 0.5 MPa, 10 Optison PS 20-100 nm; - MCF-7 cells
Hz PRF, 1050% DC, CdSe QD 20 nm and spheroids
1090 s
[57] Philips TIPS 1 MHz, 7MPa, 5 Lipid liposomes, calcein, B−A Canine blood
focused pulses, 100,000 CPP biotinylated thrombin
[54] Spherically 2.25 MHz, 3 C pulse; Lipid liposome B−A PC3 cells
focused 5 MHz, 150 kPa, 5x106 biotinylated 100 amd 200 nm
C 3 short 1.9 MPa, B−A
5 CPP
120 s at 0.25 Hz
[95] Focused single 1.3 s at 3 MHz, 150 kPa, Lipid neutravidin coated B−A cellulose tube
element 2.25 MHz 5 C; 5 CPP biotinylated latex beads 40 and
1.5 MHz, 1.1 MPa 100 nm
[79] Single element 1 MHz, 20 C, 10kHz Polymer Fe3O4 12 nm in shell SMMC 7721
30 mm diameter PRF, 0.1- 0.75 w/cm2; 40 s cells
[167] ATL/Philips 12-5 MHz, doppler: PLA polymer nanoshard after part of
HDI 5000 MI 0.4−0.45, PRF 1000 Hz; burst; polymer np shell mda-mb 231
linear transducer MCe7 cells
[61] Sonitron 2000 1 MHz, 10% DC, 2 W/cm2 Lipid lipoplex B−A HUH7, HUH7e
biotinylated GFPLuc cells
[102] ATL/Philips 5 MHz, doppler, 1000 Hz PLA polymer nanoshard after in shell
HDI 5000 PRF, 10 Hz FR, 1.0 MI; burst mda-mb 231,
20 min scan MCe7 cells
[56] Sonitron 2000 1 MHz, 20% DC,2 W/cm2; Lipid Thiol liposome M−T BLM cells
10-15 s functionalized 200 nm
[62] Sonitron 2000 1 MHz, 2 W/cm2, Lipid mRNA lipoplex B−A dendritic cells
50% DC, 30 s biotinylated
[114] Sonitron 2000 1 MHz, 50% DC, 2 W/cm2; Lipid- liposome B−A BLM, HUH-7
15 s 0.17 MPa, 0.17 MI biotinylated cells
[60] Sonitron 2000 1 MHz, 10% DC, 2 W/cm2; Lipid cationic liposomes, B−A , PAEC, PVSMC
10 s biotinylated lipoplexes, siPlexes cells
125- 325 nm
[117] Unspecified 2 W/cm2, 50% DC, 30 s Lipid rapamycin SPIO in shell PAEC, PVSMC
Rich-Mar system nanoparticle cells
[113] Sonitron 2000 1MHz, 10% DC, 2 W/cm2; lipid liposome- siPlex B−A HUH7, HUH7e
10 s biotinylated GFPLuc cells
[59] Topteam 161 PRF 100 Hz, 0.5 W/cm2, Sonovue mPEG-PLGA-PLL - RPEJ cells
60 s, 50% DC containing siRNA
[112] Sonitron 2000 1 MHz, 10% DC, 2 W/cm2, lipid- Liposome- siplex B−A, BLM cells
10 s biotinylated 120 nm
[168] Focused 1 MHz 1 MHz,100 s PRP, 40 CPP Lipid-thiol M−T U-87 MG cells
30 s 200−600 kPa functionalized
[169] 20 mm probe 1 MHz, 20% DC, 1.65 W/cm2, Lipid- liposome- dox B−A MCF-7/ADR
0.35 MPa, 15 s biotinylated cells
[170] Sonitron 1 MHz, 50% DC, 600 kPa, Lipid-thiol liposomes M−T HMB2, BLM
functionalized cells
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Table A.2: Summary of In Vivo Studies. Abbreviations used in the table cycle :(C),
cycles per pulse (CPP), duty cycle (DC), pulse repetition frequency (PRF), peak to
peak (p-p), quantum dots (QD), frame rate (FR), pulse length (PL), pulse repetition
period (PRP), polystyrene (PS), biotin-avidin (B-A), and maleimide-thiol (M-T).
Ref. Transducer Settings MB NP Linked? Model
[115] Focused 1.0-MHz 10 ms PL, 1% DC, 1 Hz SonoVue Doxil (100nm) - Balb/c mouse;
38 mm diameter PRF,120 s, 1.2 MPa CT-26 tumor
[53] Focused 1.0 MHz 10 ms PL, 1% DC, 1 Hz SonoVue Lipid coated QD - Balb/c mouse;
38 mm diameter PRF, 120 s, 1.2 MPa 30- 180 nm - CT-26 tumor
[98] Focused 1.0-MHz 10 ms PL, 1% DC, 1 Hz Sonovue Lipid coated QD - Balb/c mouse;
38 mm diameter PRF,120 s , 1.2 MPa 130 nm CT-26 tumor
[111] not specified 1 MHz, 1 v p-p pulse Albumin PS or PLGA - c57BL/6J mice
every 3 s for 150 s (100 nm) hind limb
[58] Unfocused 0.75 in 1 MHz, 5 pulses, 300 CPP, Albumin PLGA carboiimide Balb/c mice
diameter, 1 MHz 1 v p-p, every 5 s chemistry hind limb
for 12 min; 0.75 MPa - wistar rats
[87] Sonnos 5500, S3 1.3 MHz, 1.8 MPa , 110 PESDA FL spheres wistar rats
broadband lines in 50 ms 4 C over 3 us 30 nm,
transducer 100 nm
[86] HDI 3000cv 2.3 MHz, 4 C pulse over Optison polymer spheres - Sprague-dawley
0.1 ms; 128 lines forming 205 nm, 503 nm rats
90 ◦ sector
[167] ATL/Philips ; 5 MHz, Doppler: PLA polymer nanoshard after part of shell VX2 liver
HDI 5000 MI 1.0, 20 min scan burst; cancer
rabbits
[102] ATL/Philips 5 MHz, Doppler, 1000 Hz PLA polymer nanoshard in shell VX2 liver
HDI 5000 PRF, 10 Hz FR, 1.0 MI; after burst cancer
20 min scan tumor rabbits
0.17 MPa, 0.17 MI
[171] Focused: Philips 1 MHz, 1 MPa, 6 min Definity liposomes, dox - MDA-MB-231-luc
TIPS 6 scans cells SCID mice
Sonicator 740 2 min BALB/c mice
[110] focused 1 MHz, 100 C, 1 v p-p, Optison Polymer - Sprague-Dawley
single element 0.75 MPa microspheres rats
(100nm)
[116] ATL/Philips 5 MHz, Doppler PLA polymer Nanoshard; part of shell ACI rats,
HDI 5000 MI 0.4-0.45, 400 nm 3924 tumors
linear transducer 1000 Hz PRF, 20 min
[147] Focused, 1 MHz, 10 ms PL, 1% DC, lipid QD, lipsome, PX B−A Balb/c mie
single element 1 Hz PRF, 10 min biotinylated 4T1 tumor
300 KHz; 2 W/cm2;
20 min
[172] spherically 0.5 MHz, 1.2 MPa, 6% DC, SonoVue liposomes C57BL6 mice
focused .5 Hz PRF, 4 min B16-F10-luc
tumors
[173] MyLab90 2.5 MHz, 0.9 MI SonoVue PEG PLA Kun-Ming mice
[174] Sonidel Sp100 1 MHz, 100% DC, Lipid-thiol liposomes M−T NMRI mice
2-5 W/cm2, 2 min,.39 MPa functionalized
[145] Unfocused 1 MHz, 100 CPP, Covalent C57BLJ6/Rag-1
0.75 in diameter 5 s for 60 min Albumin PLGA Bond mice, C6 glioma
1.2 MPa
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APPENDIX B
Effect of Anesthesia Carrier Gas on In Vivo Circulation Times of
Ultrasound Microbubble Contrast Agents in Rats
B.1 Introduction
Microbubble contrast agents (MCAs) are currently implemented in many ultrasound
imaging studies to provide enhanced resolution of a vascular network [175; 176; 177]
as well as to act as vehicles for therapeutic applications [26; 178] . These contrast
agents are lipid-encapsulated gaseous microspheres, ranging in diameter from 1 to 10
µm. Their ability to improve an image’s quality is due to the difference in acoustic
impedance between their gaseous core and the surrounding medium. The impedance
difference, as well as their compressibility, causes MCAs to be very echogenic, where
even a single microbubble can be detected [178; 70; 179].
The nonlinear behavior of MCAs in response to ultrasound pulses allows their scat-
tered echoes to be separable from tissue, providing a high contrast to tissue ratio.
MCAs have been applied in a wide range of imaging studies including assessing my-
ocardial perfusion [180; 181], imaging blood-perfusion in tumors [12; 182] and molecular
targeting of angiogenesis or inflammation [4; 183; 184; 185].
c© 2011 John Wiley and Sons, Ltd. Reprinted, with permission, from L Mullin, R Gessner, J
Kwan, M Kaya, MA Borden and PA Dayton, “Effect of anesthesia carrier gas on in vivo circulation
times of ultrasound microbubble contrast agents in rats,” Contrast Medial Mol Imaging, 2011; 6(3):
126-131.
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Other applications of microbubble vehicles include acting as therapeutic delivery
mediators, where microbubbles carry a gene or drug on or within their shell [26; 160;
69; 96]. Microbubbles can also be applied in conjunction with therapeutic compounds
to enhance drug or gene delivery across the vascular endothelium [70].
The ability of an MCA to either enhance imaging of blood perfusion or act as ther-
apeutic mediator is maintained only as long as it is freely circulating and intact in the
bloodstream, or intentionally deposited at a localized site. Therefore, if administration
is through a bolus injection, the time window for ultrasound imaging or therapeutics is
integrally correlated to the in vivo circulation times of the microbubbles. It has been
hypothesized that the short in vivo and in vitro lifetimes of MCAs are a rate-limiting
step for advancing ultrasound contrast technology as quickly as other contrast imaging
modalities, such as X-ray and MRI [186]. Under normal physiological conditions, an
injected microbubble’s lifetime is a function of both compositional and environmental
variables. Studies have shown that the makeup of a bubble’s lipid shell and the con-
tent of the gas core affect its lifetime [128; 187], while environmental factors such as
the acoustic waveforms incident on the bubble [188], dissolved gas concentration in the
blood [189; 190], and immune response [191] also play critical roles. Recent attempts
to improve the composition of microbubbles include using higher molecular weight and
less soluble filling gasses [187; 192], and altering the chemical composition of the mi-
crobubble’s lipid shell [193; 128]. Increasing the circulation lifetimes would improve the
ability to perform consistent imaging studies over time with a bolus injection, as well
as improve the window in which both diagnostic and therapeutic applications can be
applied.
One possible method to improve the environmental conditions for injected MCAs
during studies in anesthetized animals is by changing the dissolved gas concentration of
an animal’s blood. It is well known that the gas saturation in the medium surrounding
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the microbubble affects the gas core’s dissolution rate [193; 194; 195]. Early stud-
ies with first-generation contrast agents demonstrated that MCAs circulating in dogs
that inhaled different anesthesia carrier gases had different circulation times [189; 190].
These previous studies examined two albumin-shelled agents, Albunex and Optison,
and observed circulation persistence for different ratios of two common selections for
anesthesia carrier gas: medical air and pure oxygen. In both studies, the imaging con-
trast provided by these two types of MCAs was diminished by the use of pure oxygen
as a carrier gas compared with the contrast provided by the same MCA type in the
same animal breathing medical air as the carrier gas.
In this paper we extend these early studies from albumin shelled contrast agents
to newer lipid-shelled perfluorocarbon filled contrast agents. Additionally, we examine
the effects of inhaled anesthesia gas on injected MCAs in a rodent model. Rodents
are commonly used as preclinical models of cancer and other diseases, and as such, are
frequently selected as subjects in ultrasound contrast imaging studies. The purpose
of this study was to elucidate the extent and significance of the relationship between
anesthesia carrier gas composition and MCA circulation lifetime in rats.
B.2 Experimental
B.2.1 Gas Diffusion Model
To investigate whether gas diffusion could account for differences in MCA lifetime,
a mathematical model previously developed by Kwan and Borden [196] was employed
which predicts the size of a microbubble suddenly immersed in a multi-gas environment,
such as a PFB microbubble injected into blood. This model assumes that each gas
acts independently to equilibrate at the gas-liquid interface and diffuse along its own
chemical potential (partial pressure) gradient. All gases contribute to the total pressure
and volume of the MCA gas core. Gas diffusion occurs through a stagnant aqueous
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layer equal in thickness to the microbubble radius (i.e. it is a purely diffusing sphere).
Because the animal was breathing, the impact of the microbubble injection (2 µl gas) on
the dissolved gas contents of the blood pool was considered negligible. A set of coupled,
nonlinear differential equations results from (i) a species balance over the microbubble,
(ii) the diffusion equation, (iii) the Laplace pressure equation and (iv) the ideal gas law.
Applying a finite difference method, the set of equations is discretized to the following
form:
where N is the total number of gas species; τ is the numerical time step; R is the mi-
crobubble radius; σ is the microbubble surface tension; PH is the hydrostatic pressure;
B is the universal gas constant; T is temperature; ni is the moles; Di is the diffusion
coefficient; KH,i is Henry’s constant; P∞,i is the partial pressure at saturation; and fi
is the ratio of the bulk dissolved gas content to that at saturation, each of component
i. Solving equations (1) and (2) numerically allows prediction of the growth and dis-
solution of a microbubble subject to the simultaneous influx and eﬄux of different gas
species as the system tends toward thermodynamic equilibrium, which occurs when
the partial pressures in the gas core and surrounding medium are equal for all species.
A variable time step was used to ensure that the moles inside the microbubble did
not become negative. To determine the number of moles in the bubble, a forward wind
difference method was applied, as seen in equation (1), which is solved step-wise. Equa-
tion (2) is non linear and was solved using a Newton-Raphson method (100 iterations).
In the simulation, 100 iterations were used in the Newton-Raphson method. Finally, it
should be noted that the model is limited in that it neglects the effects of convection
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in the surrounding medium, variations in blood gas concentrations and pressure as the
microbubble passes through the venous-arterial circuit, and effects of the encapsulating
shell, such as gas permeation resistance and viscous and elastic terms accounting for
lipid monolayer expansion, break-up, compression, buckling and collapse.
B.2.2 Animal Preparation
Animals were handled according to National Institute of Health guidelines and our
study protocol was approved by the UNC Institutional Animal Care and Use Commit-
tee. Five female Sprague Dawley rats (Harlan; Indianapolis, IN, USA) were imaged
throughout the course of this study. Before imaging an animal, it was first anesthetized
in an induction chamber by introducing an aerosolized 5% isoflurane oxygen mixture.
Once sedated, the animal was removed from the induction chamber, the isoflurane
concentration was reduced from 5 to 2% and then maintained via mask delivery. Its
abdomen was shaved with an electric clipper and a depilating cream was applied to the
animal’s skin to dissolve any remaining hair that would interfere with the ultrasound
image. A 24 gauge catheter was then inserted into the animal’s tail vein for the admin-
istration of MCAs. The animal was placed in dorsal recumbency on a heating pad, and
ultrasound coupling gel was placed between the imaging transducer and the animal’s
skin to ensure the quality of signal transmission.
B.2.3 Contrast Agent Preparation and Administration
A lipid mixture 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-distearoyl-
sn-glycero-3 phosphoethanolamine-N-[methoxy- (polyethylene glycol)-2000] (ammonium
salt; DSPE- PEG2K; Avanti Polar Lipids) was prepared using a 9:1 molar ratio, simi-
lar to a previously described method [128]. Briefly, lipids were dissolved in chloroform,
dried and dissolved into a buffer solution of PBS. The lipid solution was then trans-
ferred into vials, which were then evacuated and filled with decafluorobutane gas. Vials
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were shaken with a Vialmix shaker (Bristol-Myers Squibb Medical Imaging, North Bil-
lerica, MA, USA) for 45 s prior to injection. MCAs, of mean diameter 0.84 ± 0.34 µm,
were withdrawn directly from the vial with the vial vent connected to a bag filled with
decafluorobutane, to ensure that no air entered the headspace of the vial. Aliquots of
25 µl of MCAs were administered through the tail vein, followed immediately by a 200
µl flush of sterilized saline.
B.2.4 Image Acquisition
The kidneys of the rats were selected as the imaging location for this study because
of their proximity to the skin’s surface and the high concentration of vasculature. The
clinical system used to acquire all ultrasound images in this study was an Acuson
Sequoia 512 (Siemens, Mountain View, CA, USA). B-mode images were collected at
14 MHz using a linear array transducer (model 15L8). Contrast agents were imaged
in CPS mode operating at 7 MHz and a mechanical index of 0.18. CPS provides a
high contrast-to-tissue ratio while being minimally destructive to MCAs. Video data
collection started prior to a bolus injection of MCAs, and continued for up to 20 min
to allow a majority of the microbubbles to be cleared by the animal. If there were still
MCAs visibly circulating in the image after 20 min, data collection was prolonged to
accommodate the longer MCA persistence. Data by Killam et al. [197] showed that,
after Optison injection into canines, the octafluoropropane was eliminated after a mean
residence time of 38-46 s. As our model clearly shows, PFB rapidly dissolves from the
microbubble and is replaced by the blood gases. It is therefore reasonable to assume
that PFB is eliminated from the blood between contrast agent injections, which are 20
min apart.
After the completion of all measurements for an animal, the imaging study was
closed and the data exported from the ultrasound system in DICOM format. These
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files were later analyzed oﬄine in MATLAB. Multiple imaging sequences were obtained
of each anesthetized rat. An imaging sequence included the collection of two runs of
data, one breathing oxygen and one breathing air, each beginning with an injection of
MCAs and lasting until contrast agents were no longer visibly circulating. The order
of carrier gas administration was randomized for all the animals. After the completion
of the first run, the anesthesia carrier gas was changed and the animal was given 10
min to acclimate to this new carrier gas before initiating the second imaging sequence
[190]. The imaged sequence was repeated twice more to obtain a total of three imaging
sequences for each carrier gas.
B.2.5 Monitoring Physiological Changes
Blood samples were collected to determine the extent of the relationship between
dissolved blood gas partial pressures of oxygen, nitrogen, carbon dioxide and anesthesia
carrier gas. Arterial blood samples were obtained from the tail and tested immediately
after collection in a pH/blood gas analyzer (Chiron Diagnostics, Emeryville, CA, USA).
Each sample was collected only after the animal had acclimated to the anesthesia carrier
gas being tested.
B.2.6 Measuring Microbubble Circulation Time
All video data were exported from the ultrasound system and imported into MAT-
LAB for analysis. Regions of interest (ROIs) were defined around the perimeter of the
kidney of each animal, and the mask applied to every frame of data. All data were
examined to ensure there were no gross movements in tissue to cause inaccuracies in
the ROI. The mean pixel intensity within the ROI was computed and plotted as a
function of time. An example of this data is displayed in Figure B.1. To compute a
pre-contrast baseline value, the mean pixel intensity of the ROI was averaged prior to
the bolus injection of MCAs. After the MCAs were injected, the mean pixel intensity
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rose sharply to a single peak value as the bolus entered through the ROI, then decline
as the bubbles became distributed throughout the animal’s body and cleared from the
system. As the population of injected MCAs began to decline, the grayscale pixel
intensity in the ROI also decayed steadily from the initial peak down to the original
baseline value. Using MATLAB, a fourth-order interpolation polynomial was fitted to
the data following the peak value in the run. Two metrics were used to quantify the
circulation times of the injected MCAs: half-life and time to 25% intensity (t0.5Imax and
t0.25Imax respectively). These were defined as the difference between the injection time
(as determined by the highest mean intensity value in the dataset) and the times at
which the data had dropped to the points either halfway to baseline (t0.5Imax) or 75%
of the way to baseline (t0.25Imax) [191].
Measurements were repeated three times for each type of carrier gas on each animal
to determine the effect of anesthesia carrier gas. These MCA circulation times for the
two types of gases were compared between each animal. A paired two-sample Student’s
t-test was used to validate the statistical significance of the difference in circulation
times of the injected MCAs between the two types of carrier gas.
B.3 Results
B.3.1 The Effect of Carrier Gas Composition on MCA Lifetime In Vivo
Six imaging studies were completed for each animal, with each study consisting of a
single bolus injection of contrast. Circulation times, obtained from intensity curves (Fig.
B.1), were compared for medical air and oxygen. A statistically significant difference
(p<0.05) was observed for MCA circulation time as a function of anesthesia carrier gas
in four out of five animals (Fig. B.2). Circulation time in the cases for which the data
was not significant illustrated the same trend as in the other animals. Administering
medical air as the anesthesia carrier gas caused the contrast agent half-life to be an
110
average of 1.8 ± 0.1 times longer than when using pure oxygen. A greater difference
was observed when examining time to 25% peak intensity; the t0.25Imax was 2.2 ± 0.2
times longer when the animal was breathing medical air compared with breathing pure
oxygen.
Figure B.1: A comparison of intensity curves obtained from animal 3 while breathing
air compared with breathing oxygen is shown. The differences between the intensity
curves is representative of results seen in all animals.
B.3.2 Relationships Between Carrier Gas and Physiology
Dissolved blood oxygen and carbon dioxide gas partial pressures were measured in four
animals to observe any partial pressure differences between animals breathing pure
oxygen and medical air (Fig. B.1). The largest effect of carrier gas on these variables
was with pO2, as the average value was over six times higher when breathing oxygen
compared to medical air. The sum of partial pressures (
∑
pi) indicated a greater degree
of ventilation/ perfusion mismatch for oxygen-breathing rats than for air-breathing rats,
as may be expected [198; 199].
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Table B.1: Mean partial pressures of dissolved O2 and CO2 gasses in arterial blood
were measured from animals anesthetized with the two different carrier gases. The
values for N2 and H2O were taken from literature [198; 199].
∑
pi is the sum of partial
pressures. The pO2 increased above the normal range while breathing pure oxygen,
but the pCO2 remained constant. Ventilation/perfusion mismatch increased for rats
breathing pure oxygen, as expected [198; 199]. These values were used to simulate the
dissolution times of a single MCA within the different mixed gas environments.
pO2 pCO2 pN pH2O
∑
pi
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
Normal range 80-100 32-35 555-585 47 714-777
Breathing air 70 ± 6 63 ± 9 560 47 740
(n=4)
Breathing oxygen 546 ± 45 61 ± 15 0 47 654
(n=3)
One might hypothesize that the longer circulation times may be due to vasculature
changes induced by the different inhaled anesthesia carrier gases. However, based on
the measured blood gas values, shown in B.1, it does not appear that vascular changes
are contributing to the increased MCA circulation lifetime. CO2 partial pressure levels
have been shown to be related to changes in vasculature dilation [200], but these values
stayed relatively constant regardless of the administered carrier gas. Other factors
that could potentially influence circulation time, such as breathing rate, heart rate and
body temperature, were investigated. Preliminary studies (data not shown) showed no
correlation between breathing rate, heart rate, body temperature and circulation times.
B.3.3 Simulations of MCA Circulation Time
To gain physical insight, we modeled microbubble dissolution times in blood by con-
sidering pure diffusion (no convection) of the different gas species into and out of the
bubbles, as others have reported previously [201; 187]. Equations (1) and (2) were
solved numerically using the Newton-Raphson method and MATLAB software (Math-
Works, Natick, MA) for a 2, 5 and 10 µm diameter microbubble initially filled with
pure perfluorobutane (PFB) and suddenly immersed in blood. Blood gas (O2, N2, H2O
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and CO2) partial pressure values were taken from B.1 to simulate oxygen vs air as the
carrier gas. The surface tension was set to 0 mN/m [194], and the hydrostatic pressure
was set to 760 mmHg.
Figure B.3 shows the simulation results for the two carrier gases. Theory predicted
that a 2 µm diameter microbubble survives approximately 3.2 times longer when med-
ical air is used instead of oxygen (Fig. B.3). As the diameter was increased to 10
µm, the microbubble lifetimes were predicted to be 126 s for oxygen breathing and
409 s for air-breathing, which was in good general agreement with the experimental
in vivo imaging data. Inspection of the microbubble contents over time provided an
explanation for the extended lifetime B.4. Initially, the blood gases rapidly diffused
into the microbubble just as PFB, which has a much lower solubility and diffusivity in
water, slowly dissolved away. The inrush of blood gases resulted in rapid microbub-
ble growth. Microbubble growth could not be measured acoustically here due to the
complexity of the in vivo backscattered signal. However, microbubble growth has been
predicted and measured as an increase in ultrasound attenuation in a more idealized
system by Sarkar et al. [202; 203]. The presence of nitrogen extended the growth phase
by not only adding to the volume, but also diluting the other gas species, resulting in
greater accumulation of the other blood gases and reduction in the rate of PFB eﬄux.
After a short time, the microbubble was mainly composed of blood gases, and PFB
contributed only slightly to the total volume. Eventually, all gases began to eﬄux from
the microbubble as PFB dissolution continued and the partial pressures of O2, N2, and
CO2 in the gas core exceeded the partial pressures in the surrounding blood. The dis-
solution rate was accelerated for the oxygen-carrier case owing to the greater degree of
ventilation/perfusion imbalance. The sum of the partial pressures for oxygen-breathing
(653 mmHg) was much lower than for air-breathing (740 mmHg). Since the ambient
pressure was approximated to be 760 mmHg, the oxygen-breathing case represented a
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greater deviation from equilibrium and therefore a greater driving force for microbubble
dissolution. We should note that the simplified model is limited when making direct
comparisons to in vivo contrast persistence data.
The calculation ignores the gas permeation resistance of the shell and assumes a
constant surface tension (although near zero), which may not be true during the multi-
ple regions of growth and dissolution that bubbles would experience [196]. Additionally,
the calculations only take into account a single bubble under no-flow conditions. It is
possible that a population of bubbles is more stable than a single bubble. The over-
lapping diffusion zones between neighboring microbubbles will influence their rate of
dissolution, and there may be more subtle effects at play such as Ostwald ripening.
These assumptions, along with activity of other clearance mechanisms like the reticu-
loendothelial system (RES), could account for observed circulation times being longer
than the model predicts. Despite the limitations of the model, it clearly illustrates
different responses due to different gases, which agrees with experimental data.
B.4 Discussion and Conclusion
A relationship between the anesthesia carrier gas and the in vivo lifetime of injected
MCAs was observed within the five animals tested in this study. Each animal was
administered three doses of MCAs under each type of carrier gas medical air and pure
oxygen and the persistence of these contrast agents was monitored following injection.
Half-life values and time to 25 percent intensity were calculated. Medical air was found
to significantly increase the circulation time of ultrasound MCAs. The numerical results
obtained using a model obeying classical Fickian diffusion with multiple gas species
aligned with the experimentally measured values, suggesting that diffusion plays a key
role in the reduced circulation time of injected MCAs in pure oxygen breathing animals.
The effects of diffusion for the oxygen breathing case are manifest as an increased
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driving force (i.e. ventilation/perfusion mismatch) and more rapid mass transfer (i.e.
absence of an inert filling gas) for microbubble dissolution. This study illustrated that
a simple change of an anesthesia carrier gas has the potential to improve the efficacy
of ultrasound studies, both imaging and therapeutic.
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Figure B.2: Side by side comparison of the average injected MCA circulation times
for each animal. (A) Average half-life and (B) average time to 25% for each animal
inhaling the respective anesthesia carrier gases. The average circulation times when an
animal was breathing isoflurane carried by medical air were significantly longer in most
animals (*p<0.05).
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Figure B.3: Simulated response of a PFB microbubble suddenly immersed in arterial
blood. The dissolved gas parameters used in these simulations, summarized in B.1,
were based on measured values. Microbubble diameter was normalized by the initial
value shown.
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Figure B.4: Simulated response of a PFB microbubble suddenly immersed in arterial
blood. The dissolved gas parameters used in these simulations, summarized in B.1,
were based on measured values. Molar contents of each gas are plotted vs time for (A)
medical air and (B) oxygen as the carrier gas.
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